EP2064183A2 - Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity - Google Patents

Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity

Info

Publication number
EP2064183A2
EP2064183A2 EP07841847A EP07841847A EP2064183A2 EP 2064183 A2 EP2064183 A2 EP 2064183A2 EP 07841847 A EP07841847 A EP 07841847A EP 07841847 A EP07841847 A EP 07841847A EP 2064183 A2 EP2064183 A2 EP 2064183A2
Authority
EP
European Patent Office
Prior art keywords
compound
phenyl
mmol
group
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07841847A
Other languages
German (de)
French (fr)
Inventor
Richard L. Beard
John E. Donello
Haiqing Yuan
Xiaoxia Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of EP2064183A2 publication Critical patent/EP2064183A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Definitions

  • the present invention relates to derivatives and/or analogues of sphingosine and pharmaceutical compositions, including such derivatives and/or analogues, which are useful as drugs for the treatment of fungal infections, allergic diseases, immune disorders, etc.
  • Sphingosine is a compound having the chemical structure shown in the general formula described below, in which Y 1 is hydrogen. It is known that various sphingolipids, having sphingosine as a constituent, are widely distributed in the living body including on the surface of cell membranes of cells in the nervous system.
  • a sphingo lipid is one of the lipids having important roles in the living body.
  • a disease called lipidosis is caused by accumulation of a specified sphingo lipid in the body.
  • Sphingolipids present on cell membranes function to regulate cell growth; participate in the development and differentiation of cells; function in nerves; are involved in the infection and malignancy of cells; etc. Many of the physiological roles of sphingolipids remain to be solved.
  • ceramide a derivative of sphingosine, has an important role in the mechanism of cell signal transduction has been indicated, and studies about its effect on apoptosis and cell cycle have been reported.
  • Sphingosine- 1 -phosphate is an important cellular metabolite, derived from ceramide that is synthesized de novo or as part of the sphingomeyeline cycle (in animals cells). It has also been found in insects, yeasts and plants.
  • the enzyme, ceramidase acts upon ceramides to release sphingosine, which is phosphorylated by spingosine kinase, a ubiquitous enzyme in the cytosol and endoplasmic reticulum, to form sphingosine- 1 -phosphate.
  • the reverse reaction can occur also by the action of sphingosine phosphatases, and the enzymes act in concert to control the cellular concentrations of the metabolite, which concentrations are always low. In plasma, such concentration can reach 0.2 to 0.9 ⁇ M, and the metabolite is found in association with the lipoproteins, especially the HDL.
  • sphingosine- 1 -phosphate formation is an essential step in the catabolism of sphingoid bases.
  • sphingosine- 1 -phosphate is a potent messenger molecule that perhaps uniquely operates both intra- and inter-cellularly, but with very different functions from ceramides and sphingosine.
  • the balance between these various sphingolipid metabolites may be important for health.
  • sphingosine- 1 -phosphate promotes cellular division (mitosis) as opposed to cell death (apoptosis), which it inhibits. Intracellularly, it also functions to regulate calcium mobilization and cell growth in response to a variety of extracellular stimuli.
  • sphingosine- 1 -phosphate In common with the lysophospholipids, especially lysophosphatidic acid, with which it has some structural similarities, sphingosine- 1 -phosphate exerts many of its extra-cellular effects through interaction with five specific G protein-coupled receptors on cell surfaces. These are important for the growth of new blood vessels, vascular maturation, cardiac development and immunity, and for directed cell movement.
  • Sphingosine-1 phosphate is stored in relatively high concentrations in human platelets, which lack the enzymes responsible for its catabolism, and it is released into the blood stream upon activation of physiological stimuli, such as growth factors, cytokines, and receptor agonists and antigens. It may also have a critical role in platelet aggregation and thrombosis and could aggravate cardiovascular disease.
  • physiological stimuli such as growth factors, cytokines, and receptor agonists and antigens. It may also have a critical role in platelet aggregation and thrombosis and could aggravate cardiovascular disease.
  • the relatively high concentration of the metabolite in high-density lipoproteins (HDL) may have beneficial implications for atherogenesis.
  • sphingosine-1 - phosphate together with other lysolipids such as sphingosylphosphorylcholine and lysosulfatide, are responsible for the beneficial clinical effects of HDL by stimulating the production of the potent antiatherogenic signaling molecule nitric oxide by the vascular endothelium.
  • lysophosphatidic acid it is a marker for certain types of cancer, and there is evidence that its role in cell division or proliferation may have an influence on the development of cancers.
  • Fungi and plants have sphingolipids and the major sphingosine contained in these organisms has the formula described below. It is known that these lipids have important roles in the cell growth of fungi and plants, but details of the roles remain to be solved.
  • derivatives of sphingo lipids and their related compounds exhibit a variety of biological activities through inhibition or stimulation of the metabolism pathways. These compounds include inhibitors of protein kinase C, inducers of apoptosis, immuno-suppressive compounds, antifungal compounds, and the like. Substances having these biological activities are expected to be useful compounds for various diseases.
  • the present invention provides a derivative or analogue of sphingosine that is able to regulate the functions of sphingo lipid, and pharmaceutical compositions comprising said derivative or analogue.
  • X is selected from the group consisting of CR 3 , N and NO;
  • Y is selected from the group consisting of CR , N and NO;
  • Z is selected from the group consisting of CR 3 , N and NO; and at least one of X, Y and Z is N or NO; V is O or NOR 4 R 1 is an aryl group; R 2 is an aryl group;
  • R 3 is selected from the group consisting of H and alkyl; and 2 of said R 3 groups may together form a cyclic alkyl ring having from 3 to 6 carbon atoms;
  • R 4 is selected from the group consisting of H and alkyl; a is 0 or an integer of from 1 to 6; b is 0 or 1 ; c is 0 or 1 ; f is 0 or an integer of 1 or 2; x is 0 or 1 ; y is 0 or an integer of from 1 to 3; and z is 0 or an integer of from 1 to 3.
  • Specific Examples of the compounds of formula I include
  • R H, alkyl (1 1 ) Seperated by MPLC
  • R 1 , R 2 , R 3 H, alkyl
  • a diphenylethyl-l,2-dione e.g. benzil
  • methyl oxalamidrazonate in ethanol e.g. benzil
  • methyl oxalamidrazonate in ethanol e.g. 1,3-bis(trimethyl)
  • methyl 5,6-diphenyl-l,3,4-triazine-2- carboxylate as a mixture of geometric isomers if the dione is asymmetrical.
  • These triazines can undergo Diels-Aler reactions with a pyrrolidine enamine compound to give a methyl 5,6-diphenylpyridine-2-carboxylate derivative.
  • aldehyde derivatives can be reduced with diisobutylaluminum hydride to the corresponding aldehyde derivatives, which then can be converted into a number of homo logs and derivatives.
  • the aldehyde can be converted into a secondary amine by reacting it with a primary amine in the presence of a reducing agent, such as sodium cyanoborohydride.
  • a reducing agent such as sodium cyanoborohydride.
  • the aldehyde may be reduced to an alcohol and treated with an alkyl halide in the presence of a mild base to produce alkyl ethers.
  • these compounds may be used to prepare many other homo logs, many of which are described in the Specific Examples section below.
  • reference to a compound should be construed broadly to include pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of the depicted structure or chemical name.
  • a pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human.
  • a pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
  • a salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
  • a prodrug is a compound which is converted to a therapeutically active compound after administration. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group.
  • Prodrug preparation is well known in the art. For example, "Prodrugs and Drug Delivery Systems,” which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496-557, provides further detail on the subject.
  • Tautomers are isomers that are in rapid equilibrium with one another. For example, tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion. Unless stereochemistry is explicitly depicted, a structure is intended to include every possible stereoisomer, both pure or in any possible mixture.
  • Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein.
  • alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
  • Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
  • R 3 and R 4 may be independently selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, cycloalkyl having 3 to 6 carbons, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds, aryl, preferably a carbocyclic aryl group having from 6 to 14 carbon atoms or a heterocyclic aryl group having from 2 to 14 carbon atoms and from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, halo, e.g. fluoro or chloro, Ci to C ⁇ haloalkyl, e.g.
  • R 1 and R 2 are aryl groups which may be any carbocyclic aryl or heterocyclic aryl group including but not limited to benzene, pyridine, pyrazine, pyridazine, pyrimidine, triazine, thiophene, furan, thiazole, thiadiazole, isothiazole, oxazole,oxadiazole, isooxazole, naphthalene, quinoline, tetralin, chroman, thiochroman, tetrahydroquinoline, dihydronaphthalene, tetrahydronaphthalen, chromene, thiochromene, dihydroquinoline, indan, dihydrobenzofuran, dihydrobenzothiophene, indene, benzofuran, benzothiophene, coumarin and coumarinone.
  • Such aryl groups can be bonded to the above moiety at any position.
  • Such aryl group may itself be substituted with any common organic functional group including but not limited to alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, hydroxyl, alkoxyl, alkylcarbonyl, formyl, oxycarbonyl, carboxyl, alkyl carboxylate, alkyl amide, aminocarbonyl, amino, cyano, diazo, nitro, thio, sulfoxyl, or sulfonyl groups.
  • the carbocyclic aryl group will comprise from 6 to 14 carbon atoms, e.g. from 6 to 10 carbon atoms.
  • the heterocyclic aryl group will comprise from 2 to 14 carbon atoms and one or more, e.g. from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • Rl is selected from the groups consisting of phenyl and substituted derivatives thereof;
  • R 2 is selected, preferably from the group consisting of phenyl, furanyl, thienyl, pyridyl, pyranyl and substituted derivatives thereof;
  • R is selected from the group consisting of H and lower alkyl
  • R 4 is selected from the group consisting of H and lower alkyl; and a is 0 or an integer of from 1 to 3.
  • R 3 is H.
  • R 1 is represented, preferably, by the general formula
  • R 5 is selected from the group consisting of H, alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g.chloro, and loweralkylthio.
  • R 2 is selected from the group consisting of furanyl, thienyl, pyridyl and pyranyl or R 2 is
  • R 5 is selected from the group consisting of H, alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g. chloro, and loweralkylthio .
  • X and Y are CR 3 and Z is N.
  • the compounds have a side chain which is terminated with carboxylic acid or carboxylic ester group, i.e. b is 0, c is 1, xis 1, y is 1 and z is 0.
  • a is 0 and more preferably R 4 is alkyl.
  • R 1 is a carbocyclic aryl having from 6 to 10 carbon atoms which may be substituted with an alkyl or halo alkyl group.
  • R 1 is phenyl which may be substituted with an alkyl or haloalkyl group.
  • R 2 is a carbocyclic aryl having from 6 to 10 carbon atoms which may be substituted with an alkyl or haloalkyl group or R 2 is pyridyl.
  • said alkyl group is a lower alkyl radical and said haloalkyl group is trifluoromethy 1.
  • R 3 is H
  • c is 1, 2 or 3 and a is 1.
  • Z is N
  • X and Y are CR 3
  • W is NR 3
  • R 2 is phenyl and R 5 is selected from the group consisting of H and methyl or R 2 is pyridyl and R 5 is ethyl
  • d is 0 and therefore the compounds have a side chain which terminates in a carbon-oxygen radical such as a carboxylic acid, an ester thereof, an ether, an alcohol, or an alkyl carboxy group.
  • a carbon-oxygen radical such as a carboxylic acid, an ester thereof, an ether, an alcohol, or an alkyl carboxy group.
  • R 1 may be represented by the general formula
  • R 5 is selected from the group consisting of H, alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g. chloro, and loweralkylthio
  • R 2 may also be represented by the general formula
  • R 5 is selected from the group consisting of H, lower alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g. chloro, and loweralkylthio or R 2 is selected from the group consisting of furanyl, thienyl, pyridyl and pyranyl.
  • R 3 is H and more preferably, a is 1.
  • x is 1
  • z is 0
  • R 4 is selected from the group consisting of H, methyl and ethyl.
  • the carbon-oxygen compounds of this invention preferably is Z is N, X and Y are CR 3 , R 2 is pyridyl, R 4 is selected from the group consisting of methyl and ethyl and R 5 is selected from the group consisting of H, methyl, ethyl, propyl and trifluoromethyl, or X, Y and Z are N, R 4 is selected from the group consisting of methyl and ethyl and R 5 is selected from the group consisting of H, methyl, ethyl, propyl and trifluoromethyl, or
  • X and Z are N and Y is CR
  • Me refers to methyl
  • tBu refers to t-butyl
  • iPr refers to i-propyl
  • Ph refers to phenyl
  • “Pharmaceutically acceptable salt” refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid and the like.
  • Alkyl refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon.
  • the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, most preferably 1 to 4 carbons.
  • Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like.
  • alkenyl refers to a straight-chain, branched or cyclic unsaturated hydrocarbon group containing at least one carbon—carbon double bond.
  • the alkenyl group has 2 to 12 carbons. More preferably it is a lower alkenyl of from 2 to 7 carbons, most preferably 2 to 4 carbons.
  • the alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, O, S, NO 2 , halogen, dimethyl amino, and SH.
  • Alkynyl refers to a straight-chain, branched or cyclic unsaturated hydrocarbon containing at least one carbon—carbon triple bond.
  • the alkynyl group has 2 to 12 carbons. More preferably it is a lower alkynyl of from 2 to 7 carbons, most preferably 1 to 4 carbons.
  • the alkynyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, O, S, NO 2 , halogen, dimethyl amino, and SH.
  • Alkoxyl refers to an “O-alkyl” group.
  • Aryl refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups.
  • the aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, SH, OH, NO 2 , amine, thioether, cyano, alkoxy, alkyl, and amino.
  • Alkaryl refers to an alkyl that is covalently joined to an aryl group. Preferably, the alkyl is a lower alkyl.
  • Carbocyclic aryl refers to an aryl group wherein the ring atoms are carbon.
  • Heterocyclic aryl refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen.
  • Hydrocarbyl refers to a hydrocarbon radical having only carbon and hydrogen atoms.
  • the hydrocarbyl radical has from 1 to 20 carbon atoms, more preferably from 1 to 12 carbon atoms and most preferably from 1 to 7 carbon atoms.
  • Substituted hydrocarbyl refers to a hydrocarbyl radical wherein one or more, but not all, of the hydrogen and/or the carbon atoms are replaced by a halogen, nitrogen, oxygen, sulfur or phosphorus atom or a radical including a halogen, nitrogen, oxygen, sulfur or phosphorus atom, e.g. fluoro, chloro, cyano, nitro, hydroxyl, phosphate, thiol, etc.
  • Amide refers to -C(O)-NH-R', wherein R' is alkyl, aryl, alkylaryl or hydrogen.
  • Thioamide refers to -C(S)-NH-R, wherein R is alkyl, aryl, alkylaryl or hydrogen.
  • “Amine” refers to a — N(R")R" group, wherein R" and R'" are independently selected from the group consisting of alkyl, aryl, and alkylaryl.
  • Thioether refers to — S— R", wherein R" is alkyl, aryl, or alkylaryl.
  • Compounds were also assessed for their ability to activate or block activation of the human S1P3 receptor in T24 cells stably expressing the human S1P3 receptor.
  • Ten thousand cells/well were plated into 384-well poly-D-lysine coated plates one day prior to use.
  • the growth media for the S1P3 receptor expressing cell line was McCoy's 5 A medium supplemented with 10% charcoal-treated fetal bovine serum (FBS), 1% antibiotic-antimycotic and 400 ⁇ g/ml geneticin.
  • FBS charcoal-treated fetal bovine serum
  • the cells were washed twice with Hank's Balanced Salt Solution supplemented with 20 mM HEPES (HBSS/Hepes buffer).
  • the cells were then dye loaded with 2 uM Fluo-4 diluted in the HBSS/Hepes buffer with 1.25 mM Probenecid and incubated at 37 0 C for 40 minutes. Extracellular dye was removed by washing the cell plates four times prior to placing the plates in the FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices).
  • Ligands were diluted in HBSS/Hepes buffer and prepared in 384-well microplates.
  • the positive control, Sphingosine-1 -Phosphate (SlP) was diluted in HBSS/Hepes buffer with 4 mg/ml fatty acid free bovine serum albumin.
  • the FLIPR transferred 12.5 ⁇ l from the ligand microplate to the cell plate and took fluorescent measurements for 75 seconds, taking readings every second, and then for 2.5 minutes, taking readings every 10 seconds. Drugs were tested over the concentration range of 0.61 nM to 10,000 nM. Data for Ca +2 responses were obtained in arbitrary fluorescence units and not translated into Ca +2 concentrations. IC50 values were determined through a linear regression analysis using the Levenburg Marquardt algorithm.
  • NA is defined as “Not Active”
  • ND is defined as “Not Determined”
  • % efficacy is defined as “percent of receptor activity induced by a test compound at the highest dose test (10 ⁇ M) relative to the receptor activity induced by 5 nM sphingosine-1- phosphate.”
  • % inhibition is defined as "percent of receptor activity induced by 5 nM sphingosine-1 -phosphate that is inhibited by a test compound at the highest dose tested (10 ⁇ M)."
  • SlP increases capsaicin responsiveness of DRG neurons SlP pathway, S1P3, SlPl deregulated in multiple pain models (EHT/AGN) Glaucoma
  • Angiogenesis disorders siRNA knockdown of SlPl and S1P3 inhibits angiogenesis S IP 1/3 subtypes expressed in VEC promote VEC migration promote barrier assembly and integrity
  • RuC12(PPh3)4 Na: sodium NaOEt: sodium ethoxide
  • NaBH 4 sodium borohydride
  • NaBH 3 CN sodium cyanoborohydride
  • THF tetrahydrofuran
  • Pd(PPlIs) 4 palladium tetrakis(tripenylphosphine)
  • R Me 11
  • R CF 3 14
  • R 1 H-Pr 20
  • R 2 H-C 9 H 19 10
  • R W-C 9 H 19 15
  • R 1 CF 3
  • Example 1 l-(2-p-Tolylethynyl)benzene (Compound 1).
  • General Procedure A To a solution of lithium phenylacetylide (15.2 ml, 15.2 mmol) in DME (20 ml) under Argon at -78 0 C was added triisopropoxylborane (3.5 ml, 15.2 mmol). The mixture was stirred at -78 0 C for 1.5 hours.
  • Example 2 l-(2-(4-Ethylphenyl)ethynyl)benzene (Compound 2) Following General Procedure A, lithium phenylacetylide (14.0 ml, 14.1 mmol), triisopropoxylborane (3.2 ml, 14.1 mmol), l-bromo-4-ethylbenzene (2 g, 10.8 mmol) and Pd(PPh 3 ) 4 (375 mg, 0.32 mmol) in DME (30ml) and THF (10 ml) were reacted to obtain the title compound as a yellow oil.
  • Example 4 l-(2-(4-Trifluoromethylphenyl)ethynyl)benzene (Compound 4) Following General Procedure A, lithium phenylacetylide (17.3 ml, 17.3 mmol), triisopropoxylborane (4.0 ml, 17.3 mmol), l-bromo-4-trifluoromethyl-benzene (3 g, 13.3 mmol) and Pd(PPh 3 ) 4 (462 mg, 0.40 mmol) in DME (40 ml) and THF (15 ml) were reacted to obtain the title compound as a yellow solid.
  • Example 5 l-(2-(4-n-Nonanylphenyl)ethynyl)benzene (Compound 5) Following General Procedure A, lithium phenylacetylide (12.4 ml, 12.4 mmol), triisopropoxylborane (2.8 ml, 12.4 mmol), l-bromo-4-n-nonanylbenzene (2.7 g, 9.5 mmol) and Pd(PPh 3 ) 4 (331 mg, 0.40 mmol) in DME (30 ml) and THF (10 ml) were reacted to obtain the title compound as a yellow solid.
  • Example 6 l-Phenyl-2-p-tolylethane-l,2-dione (Compound 6).
  • General Procedure B To a suspension of iodosobenzene (2.5 g, 11.3 mmol) in CH 2 Cl 2 (30 ml) was added RuCl 2 (PPh 3 ) 4 (45 mg, 0.04 mmol). A solution of 1 -(2-p-tolylethynyl)benzene (Compound 1, 835 mg, 4.3 mmol) in CH 2 Cl 2 (10 ml) was cannulated into the suspension. The resulting mixture was stirred at room temperature overnight resulting in a homogeneous solution. The solvent was removed in vacuo, and the residue was purified by silica gel chromatography (10% ethyl acetate in hexane) to produce the title compound as a yellow oil.
  • Example 7 l-(4-Ethyl-phenyl)-2-phenyl-ethane-l,2-dione (Compound 7).
  • iodosobenzene 1.5g, 6.7 mmol
  • RuCl 2 (PPh S ) 4 21 mg, 0.02 mmol
  • l-(2-(4-ethylphenyl)ethynyl)benzene Compound 2, 360 mg, 1.8 mmol
  • CH 2 Cl 2 (30 ml)
  • Example 8 l-(4-n-Propyl-phenyl)-2-phenyl-ethane-l,2-dione (Compound 8).
  • iodosobenzene 2.2 g, 10.0 mmol
  • RuCl 2 (PPhS) 4 38 mg, 0.04 mmol
  • l-(2-(4-/?-propylphenyl)ethynyl)benzene Compound 3, 860 mg, 3.9 mmol
  • CH 2 Cl 2 50 ml
  • Ethyl 5,6-Diphenyl-l,2,4-triazine-3-carboxylate (Compound 11).
  • General Procedure C A solution of ethyl oxalamidrazonate (Compound 37, 236 mg, 1.8 mmol) in ethanol (20 ml) was cannulated slowly into a stirring solution of benzil (500 mg, 2.4 mmol) in ethanol (20 ml) under argon at room temperature. After the addition was completed, the reaction was stirred at room temperature overnight ( ⁇ 16 hours). The mixture was then refluxed for 1 hour. The solvent was removed in vacuo, and the crude products was purified by column chromatography (silica gel, 20% ethyl acetate in hexane) to obtain the title compound as an oil.
  • Example 13 and Example 18 Ethyl 6-(4-Ethylphenyl)-5-phenyl -l,2,4-triazine-3-carboxylate (Compound 13), and Ethyl 5-(4-Ethylphenyl)-6-phenyl-l,2,4-triazine-3-carboxylate (Compound 18).
  • Ethyl 5-Phenyl-6-(4-propylphenyl)-l,2,4-triazine-3-carboxylate (Compound 14). Following General Procedure C, ethyl oxalamidrazonate (Compound 37, 460 mg, 1.5 mmol) and l-(4-n-propylphenyl)-2-phenyl-ethane-l,2-dione (Compound 8, 588 mg, 2.3 mmol) in ethanol (40 ml) were reacted and the product was recrystalized from 5% ethyl acetate in hexane to produce the title compound as yellow solid.
  • Example 15 and Example 19 Ethyl 6-(4-Trifluoromethyl-phenyl)-5-phenyl -1,2,4— triazine-3-carboxylate (Compound 15), and Ethyl 5-(4-Trifluoromethylphenyl)-6-phenyl- 1,2,4— triazine-3-carboxylatate (Compound 19).
  • Ethyl 6-Phenyl-5-p-tolyl-pyridine-2-carboxylate (Compound 22). Following General Procedure D, ethyl 5-phenyl-6-/?-tolyl-l,2,4— triazine-3-carboxylate (Compound 12, 177 mg, 0.56 mmol) and crude 1-vinylpyrrolidine (Compound 38, 730 mg) in CHCl 3 (10 ml) were reacted to produce the title compound as a yellow solid.
  • Ethyl 6-Phenyl-5-(4-propylphenyl)-pyridine-2-carboxylate (Compound 24). Following General Procedure D, ethyl 5-phenyl-6-(4-propyl-phenyl)- 1,2,4— triazine-3-carboxylate (Compound 14), (153 mg, 0.46 mmol) and crude 1- vinylpyrrolidine (Compound 38, 2 g) in CHCl 3 (10 ml) were reacted to produce the title compound as a yellow oil.
  • Ethyl 6-Phenyl-5-(4-trifluoromethylphenyl)-pyridine-2-carboxylate (Compound 25). Following General Procedure D, ethyl 6-(4- tirfluoromethylphenyl)-5 -phenyl -l,2,4-triazine-3-carboxylate (Compound 15), (378 mg, 1.01 mmol) and crude 1-vinylpyrrolidine (Compound 38, 780 mg) in CHCl 3 (10 ml) were reacted to produce the title compound as a yellow oil.
  • Example 26 Ethyl 5-(4-Ethylphenyl)-3-methyl-6-phenyl-pyridine-2-carboxylate (Compound 26). Following General Procedure D, ethyl 6-(4-ethylphenyl)-5- phenyl-1,2,4— triazine-3-carboxylate (Compound 13, 200 mg, 0.60 mmol) and crude 1-propenyl-pyrrolidine (Compound 39, 2 g) in CHCI3 (10 ml) were reacted to produce the title compound as a yellow oil.
  • Example 27 Ethyl 5-Phenyl-6-p-tolyl-pyridine-2-carboxylate (Compound 27). Following General Procedure D, ethyl 6-phenyl-5-/?-tolyl-l,2,4-triazine-3-carboxylate (Compound 17, 361 mg, 1.13 mmol) and crude 1-vinylpyrrolidine (Compound 38, 806 mg) in CHCl 3 (10 ml) were reacted to produce the title compound as a yellow oil.
  • Example 29 Ethyl 5-Phenyl-6-(4-trifluoromethyl-phenyl)-pyridine-2-carboxylate (Compound 29). Following General Procedure D, ethyl 5-(4- trifluoromethylphenyl)-6-phenyl-l,2,4 ⁇ triazine-3-carboxylate (Compound 19, 1 g, 2.68 mmol) and crude 1-vinylpyrrolidine (Compound 38, 1.4 g) in CHCI3 (20 ml) were reacted to produce the title compound as a yellow oil.
  • Methyl 5,6-diphenylpyridine-2-carboxylate (Compound 30).
  • General Procedure E A solution of ethyl 5,6-diphenylpyridine-2-carboxylate (Compound 21, 30 mg, 0.1 mmol) and cone. H 2 SO 4 (3 drops) in MeOH (5 ml) was heated at 50 0 C overnight. The mixture was diluted with water, and the products were extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over Na 2 SO 4 . The filtered solvent was concentrated in vacuo and the residue was purified by column chromatography (20 % ethyl acetate in hexane) to obtain the title compound as a yellow solid.
  • Methyl 5-(4-Ethylphenyl)-6-phenyl-pyridine-2-carboxylate (Compound 32). Following General Procedure E, ethyl 5-(4-ethylphenyl)- 6-phenylpyridine-2- carboxylate (Compound 23, 45 mg, 0.15 mmol) and cone. H 2 SO 4 (3 drops) in MeOH (3 ml) were reacted to produce title compound as a yellow solid.
  • Example 35 Methyl 5-Phenyl-6-(4-trifluoromethylphenyl)-pyridine-2-carboxylate (Compound 35). Following General Procedure E, ethyl 5-phenyl-6-(4- trifluoromethylphenyl)-pyridine-2-carboxylate (Compound 29, 103 mg, 0.28 mmol) and cone. H 2 SO 4 (5 drops) in MeOH (5 ml) were reacted to produce the title compound as a white solid.
  • Ethyl oxalamidrazonate (Compound 37).
  • a solution of anhydrous hydrazine (0.5 ml, 15.0 mmol) in ethanol (5 ml) was added dropwise to a stirred solution of ethyl thiooxamate (2 g, 15.0 mmol) in ethanol (45 ml) under argon at room temperature.
  • the mixture was stirred at room temperature for 1 hour, and the solvent was removed in vacuo and dried under high vacuum to get a white solid which was maintained in argon atmosphere after drying. The white solid was used in the next step without further purification.
  • Example 38 1-vinylpyrrolidine (Compound 38).
  • General Procedure F To a suspension of K2CO3 (3.8 g, 28.1 mmol) and pyrrolidine (1 g, 14.0 mmol) in toluene (10 ml) was added acetylaldehyde under argon at 0 0 C. The mixture was stirred at room temperature overnight. After filtration, the filtrate was concentrated in vacuo to yield a crude oil which was used in the next reaction without further purification.
  • Example 39 To a suspension of K2CO3 (3.8 g, 28.1 mmol) and pyrrolidine (1 g, 14.0 mmol) in toluene (10 ml) was added acetylaldehyde under argon at 0 0 C. The mixture was stirred at room temperature overnight. After filtration, the filtrate was concentrated in vacuo to yield a crude oil which was used in the next reaction without further purification.
  • Example 39 To a suspension of K2
  • the resulting white precipitate was filtered off, rinsed with THF (10 ml), and the combined filtrates were added to a solution OfNaBH 4 (945 mg, 24.9 mmol) in H 2 O (20 ml) slowly in order to maintain an internal temperature of 10 0 C to 15 0 C. After the addition was completed, the reaction was stirred at room temperature for 4 hours, and then it was made acidic with HCl (20 %). The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with NaHCO 3 (aq), and water, and brine, and dried over Na 2 SO 4 . The filtered solution was concentrated in vacuo, and the residue was purified by column chromatography (20 % ethyl acetate in hexane) to yield a white solid.
  • Example 55 and Example 60 ⁇ -Phenyl-S-p-tolylpyridine-l-carbaldehyde (Compound 55) and (6-phenyl-5-p- tolylpyridin-2-yl)methanol (Compound 60).
  • ethyl ⁇ -phenyl-S-p-tolylpyridine ⁇ -carboxylate (Compound 22, 1.1 g, 3.47 mmol) and DIBAL-H (5.2 ml, 5.21 mmol, 1.0M in cyclohexane) in CH 2 Cl 2 (30 ml) were reacted to produce Compound 55 and Compound 60 after separation by column chromatography (silica gel, 15% ethyl acetate in hexane).
  • Example 76 l-(5,6-Diphenyl-pyridin-2-yl)-propan-l-one (Compound 76).
  • ethyl 5,6-diphenylpyridine-2-carboxylate Compound 21, 267 mg, 0.81 mmol
  • toluene 5 ml
  • N, N'-dimethylethylenediamine DMEDA, 85 mg, 0.97 mmol
  • triethylaluminum 2.6 ml, 2.64 mmol, 1 M in hexane
  • Example 81 l-(5,6-Diphenyl-pyridin-2-yl)-propan-l-one Oxime (Compound 81). Following General Procedure P, l-(5,6-diphenyl-pyridin-2-yl)-propan-l-one (Compound 76, 90 mg, 0.31 mmol), NH 2 OH-HCl (87 mg, 1.25 mmol) and pyridine (272 mg, 0.27 mmol) in EtOH (2 ml) were reacted to give title compound as a white solid.
  • Example 82 l-(5,6-Diphenyl-pyridin-2-yl)-ethanone O-Methyloxime (Compound 82).
  • General Procedure Q To a suspension of NaH (20 mg, 0.80 mmol) in THF (2 ml) at 0 0 C was added a solution of l-(5,6-diphenyl-pyridin-2-yl)-ethanone oxime (Compound 80, 46 mg, 0.16 mmol) in THF (1 ml). After the mixture was stirred at the same temperature for 1 hour, MeI (140 mg, 0.99 mmol) was added and the solution was stirred overnight at room temperature.
  • Example 84 [6-Phenyl-5-(4-trifluoromethyl-phenyl)-pyridin-2-yl] -ethanone O-Methyloxime (Compound 84). Following General Procedure P, l-[6-phenyl-5-(4- trifluoromethyl-phenyl)-pyridin-2-yl]-ethanone (Compound 77, 15 mg, 0.04 mmol), NH 2 OMe-HCl (15 mg, 0.18 mmol) and pyridine (14 mg, 0.18 mmol) in EtOH (2 ml) were reacted to give title compound as a white solid. (12 mg, 75%).
  • Example 85 l-[6-Phenyl-5-(4-trifluoromethyl-phenyl)-pyridin-2-yl]-propan-l-one O- Methyloxime (Compound 85).
  • l-[6-phenyl-5-(4- trifluoromethyl-phenyl)-pyridin-2-yl]-propan-l-one (Compound 78) (24 mg, 0.07 mmol), NH 2 OMe-HCl (23 mg, 0.25 mmol) and pyridine (21 mg, 0.28 mmol) in EtOH (2 ml) were reacted to give title compound as a white solid.
  • Example 92 6-Methoxymethyl-2,3-diphenyl-pyridine (92).
  • a solution of 5,6-diphenylpyridin- 2-yl)methanol (Compound 90, 15 mg, 0.06 mmol), MeI (0.1 ml), K 2 CO 3 (50 mg) and KOH (5N, 5 drops) in acetone was heated at 56 0 C over night.
  • the mixture was diluted with water and the product was extracted with ethyl acetate. .
  • the organic layer was washed with water, and brine, and dried over Na 2 SO 4 .
  • the filtered solvent was concentrated in vacuo, and the residue was purified by silica gel chromatography (15 % ethyl acetate in hexane) to give title compound as a solid.
  • Methyl S ⁇ -Diphenyl-pyrazine-l-carboxylate (93).
  • benzyl 500 mg, 2.38 mmol
  • 2,3 -diaminopropionic acid monohydro chloride (334 mg, 2.38 mmol)
  • NaOH 380 mg, 9.51 mmol
  • H 2 SO 4 1 ml was added dropwise and the whole mixture was stirred under reflux for 3 hours. MeOH was removed and the residue was dissolved in water, extracted with ethyl acetate.
  • Example 94 l-(5,6-Diphenyl-pyrazin-2-yl)-ethanone (94).
  • methyl 5,6-diphenyl-pyrazine-2-carboxylate Compound 93, 83 mg, 0.29 mmol
  • Me 3 Al 0.4 ml, 2M in toluene
  • DMEDA 28 mg, 0.32 mmol
  • Example 95 l-(5,6-Diphenyl-pyrazin-2-yl)-propan-l-one (95).
  • methyl 5,6-diphenyl-pyrazine-2-carboxylate (Compound 93) (92 mg, 0.32 mmol), Et 3 Al (0.9 ml, IM in hexane), DMEDA (38 mg, 0.35 mmol) in toluene was reacted to afford the title compound.
  • Example 106 l-Methyl-5,6-diphenyl-lH-pyrimidin-2-one (106).
  • Example 96 Methyl 4,5-Diphenyl-pyrimidine-2-carboxylate (96).
  • Pd(OAc) 2 (2.1 mg) and DPPF (13 mg) were added and CO (g) was bubbled through the solution.
  • the reaction was heated to 110 0 C in a sealed tube for 2 days.
  • Example 109 (£)-3-(4-Isopropylphenyl)prop-2-en-l-ol (Compound 109).
  • 4-iso-propylcinnamic acid (3 g, 15.8 mmol)
  • ethyl chloro formate (1.6 ml, 15.8 mmol)
  • triethylamine (2.2 ml, 15.8 mmol) in THF (100ml) were reacted to produce a mixed anhydride, which was then were reacted with NaBH 4 (1.3 g, 34.7 mmol) in H 2 O (30 ml) to produce title compound as a white solid.
  • NaBH 4 1.3 g, 34.7 mmol
  • Example 110 (£)-3-(4-Isopropylphenyl)acrylaldehyde (Compound 110).
  • oxalyl chloride (9.5 ml, 19.0 mmol, 2M in CH 2 Cl 2 ), DMSO (1.8 ml, 25.3 mmol), (£)-3-(4-isopropylphenyl)prop-2-en-l-ol (Compound 109, 2.2g, 12.6 mmol) and triethylamine (7.1 ml, 50.7 mmol) in CH 2 Cl 2 (100 ml) were reacted to obtain the title compound as an oil.
  • Example 113 (E)-3-(Dimethylamino)-l-phenyl-2-p-tolylprop-2-en-l-one (Compound 113).
  • a solution of l-phenyl-2-/?-tolylethanone (2 g, 9.5 mmol) and dimethylformamide dimethylacetal (4.5 g, 38.1 mmol) in DMF (30 ml) was heated at 75 0 C for 24 hours. Solvents were removed under high vacuum to obtain the title compound as a yellow oil, which was used directly in the next step without purification.
  • the present invention contemplates and includes a compound comprising a 6-membered heteroaromatic ring including one, two or three enchained nitrogen atoms at the 1 , or 1 and 3 or 1 , 3 and 4 positions, respectively, and the remaining ring atoms being carbon, an aryl radical directly bonded to said 6-membered heteroaromatic ring at both of the 5 and 6 positions and a side chain at the 2 position of said 6-membered heteroaromatic ring, wherein said side chain terminates with an end group selected from the group consisting of a phosphonic acid, a lower alkyl ester thereof, a carboxylic acid, a lower alkyl ester thereof, a lower alkyl ether and a lower alkylcarboxy and a compound comprising a 6- membered heteroaro

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)

Abstract

A novel compound having agonist activity at the S1P3 receptor which is represented by the formula (I) wherein X is selected from the group consisting of CR3, N and NO; Y is selected from the group consisting of CR3, N and NO; Z is selected from the group consisting of CR3, N and NO; and at least one of X, Y and Z is N or NO; V is O or NOR4 R1 is an aryl group; R2 is an aryl group; R3 is selected from the group consisting of H and alkyl; and 2 of said R3 groups may together form a cyclic alkyl ring having from 3 to 6 carbon atoms; R4 is selected from the group consisting of H and alkyl; a is 0 or an integer of from 1 to 6; b is 0 or 1; c is 0 or 1; f is 0 or an integer of 1 or 2; x is 0 or 1; y is 0 or an integer of from 1 to 3; and z is 0 or an integer of from 1 to 3.

Description

18063-A(AP)
HETEROAROMATIC COMPOUNDS HAVING SPHINGOSINE- 1- PHOSPHATE (SlP) RECEPTOR AGONIST BIOLOGICAL ACTIVITY
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to derivatives and/or analogues of sphingosine and pharmaceutical compositions, including such derivatives and/or analogues, which are useful as drugs for the treatment of fungal infections, allergic diseases, immune disorders, etc.
2. Summary of the Art
Sphingosine is a compound having the chemical structure shown in the general formula described below, in which Y1 is hydrogen. It is known that various sphingolipids, having sphingosine as a constituent, are widely distributed in the living body including on the surface of cell membranes of cells in the nervous system.
H OH NH2
H3C - (CH2)i2 - C = CH - CH - CH - CH2O-Y1
H
A sphingo lipid is one of the lipids having important roles in the living body. A disease called lipidosis is caused by accumulation of a specified sphingo lipid in the body. Sphingolipids present on cell membranes function to regulate cell growth; participate in the development and differentiation of cells; function in nerves; are involved in the infection and malignancy of cells; etc. Many of the physiological roles of sphingolipids remain to be solved. Recently the possibility that ceramide, a derivative of sphingosine, has an important role in the mechanism of cell signal transduction has been indicated, and studies about its effect on apoptosis and cell cycle have been reported.
Sphingosine- 1 -phosphate is an important cellular metabolite, derived from ceramide that is synthesized de novo or as part of the sphingomeyeline cycle (in animals cells). It has also been found in insects, yeasts and plants.
The enzyme, ceramidase, acts upon ceramides to release sphingosine, which is phosphorylated by spingosine kinase, a ubiquitous enzyme in the cytosol and endoplasmic reticulum, to form sphingosine- 1 -phosphate. The reverse reaction can occur also by the action of sphingosine phosphatases, and the enzymes act in concert to control the cellular concentrations of the metabolite, which concentrations are always low. In plasma, such concentration can reach 0.2 to 0.9 μM, and the metabolite is found in association with the lipoproteins, especially the HDL. It should also be noted that sphingosine- 1 -phosphate formation is an essential step in the catabolism of sphingoid bases.
Like its precursors, sphingosine- 1 -phosphate is a potent messenger molecule that perhaps uniquely operates both intra- and inter-cellularly, but with very different functions from ceramides and sphingosine. The balance between these various sphingolipid metabolites may be important for health. For example, within the cell, sphingosine- 1 -phosphate promotes cellular division (mitosis) as opposed to cell death (apoptosis), which it inhibits. Intracellularly, it also functions to regulate calcium mobilization and cell growth in response to a variety of extracellular stimuli. Current opinion appears to suggest that the balance between sphingosine - 1 -phosphate and ceramide and/or spingosine levels in cells is critical for their viability. In common with the lysophospholipids, especially lysophosphatidic acid, with which it has some structural similarities, sphingosine- 1 -phosphate exerts many of its extra-cellular effects through interaction with five specific G protein-coupled receptors on cell surfaces. These are important for the growth of new blood vessels, vascular maturation, cardiac development and immunity, and for directed cell movement.
Sphingosine-1 phosphate is stored in relatively high concentrations in human platelets, which lack the enzymes responsible for its catabolism, and it is released into the blood stream upon activation of physiological stimuli, such as growth factors, cytokines, and receptor agonists and antigens. It may also have a critical role in platelet aggregation and thrombosis and could aggravate cardiovascular disease. On the other hand the relatively high concentration of the metabolite in high-density lipoproteins (HDL) may have beneficial implications for atherogenesis. For example, there are recent suggestions that sphingosine-1 - phosphate, together with other lysolipids such as sphingosylphosphorylcholine and lysosulfatide, are responsible for the beneficial clinical effects of HDL by stimulating the production of the potent antiatherogenic signaling molecule nitric oxide by the vascular endothelium. In addition, like lysophosphatidic acid, it is a marker for certain types of cancer, and there is evidence that its role in cell division or proliferation may have an influence on the development of cancers. These are currently topics that are attracting great interest amongst medical researchers, and the potential for therapeutic intervention in sphingosine-1 -phosphate metabolism is under active investigation.
Fungi and plants have sphingolipids and the major sphingosine contained in these organisms has the formula described below. It is known that these lipids have important roles in the cell growth of fungi and plants, but details of the roles remain to be solved.
OH OH NH2 H3C - (CH2)i2 - CH2 - CH - CH - CH - CH2OH
Recently it has been known that derivatives of sphingo lipids and their related compounds exhibit a variety of biological activities through inhibition or stimulation of the metabolism pathways. These compounds include inhibitors of protein kinase C, inducers of apoptosis, immuno-suppressive compounds, antifungal compounds, and the like. Substances having these biological activities are expected to be useful compounds for various diseases.
Derivatives of sphingosine have been prepared in various patents. For example, see U.S. Patents 4,952,683, 5,110,987, 6,235,912 Bl, 6,239,297 Bl.
SUMMARY OF THE INVENTION
The present invention provides a derivative or analogue of sphingosine that is able to regulate the functions of sphingo lipid, and pharmaceutical compositions comprising said derivative or analogue.
These compounds are represented by the formula I, which compounds have sphingosine- 1 -phosphate receptor agonist biological activity:
[C(R3)2]a[S(O)f{R3)]b[C(V)x(OR4)y(R4)z]c wherein
X is selected from the group consisting of CR3, N and NO; Y is selected from the group consisting of CR , N and NO;
Z is selected from the group consisting of CR3, N and NO; and at least one of X, Y and Z is N or NO; V is O or NOR4 R1 is an aryl group; R2 is an aryl group;
R3 is selected from the group consisting of H and alkyl; and 2 of said R3 groups may together form a cyclic alkyl ring having from 3 to 6 carbon atoms;
R4 is selected from the group consisting of H and alkyl; a is 0 or an integer of from 1 to 6; b is 0 or 1 ; c is 0 or 1 ; f is 0 or an integer of 1 or 2; x is 0 or 1 ; y is 0 or an integer of from 1 to 3; and z is 0 or an integer of from 1 to 3. Specific Examples of the compounds of formula I include
These compounds may be synthesized as illustrated by the synthesis scheme below: It is noted that, in the general synthetic schemes used throughout this patent application, the various substituents designated as R, R 1 , r R> 2 etc. may represent substituents which differ from the substituents that R, R1, R2 etc. represent in the above formula I. However, it will be apparent to the skilled artisan that it is intended for the definition of the invention, as claimed, that the definition of the substituents in formula I control in defining the scope of the invention, while the substituents of the general synthetic scheme are for the purpose of showing the making of the claimed compounds
R = H, alkyl (1 1 ) Seperated by MPLC
R1 , R2, R3 = H, alkyl In general, a diphenylethyl-l,2-dione (e.g. benzil) is treated with methyl oxalamidrazonate in ethanol to produce a methyl 5,6-diphenyl-l,3,4-triazine-2- carboxylate (as a mixture of geometric isomers if the dione is asymmetrical). These triazines can undergo Diels-Aler reactions with a pyrrolidine enamine compound to give a methyl 5,6-diphenylpyridine-2-carboxylate derivative. These compounds can be reduced with diisobutylaluminum hydride to the corresponding aldehyde derivatives, which then can be converted into a number of homo logs and derivatives. For instance, the aldehyde can be converted into a secondary amine by reacting it with a primary amine in the presence of a reducing agent, such as sodium cyanoborohydride. Alternatively, the aldehyde may be reduced to an alcohol and treated with an alkyl halide in the presence of a mild base to produce alkyl ethers. Those skilled in the art will recognize that these compounds may be used to prepare many other homo logs, many of which are described in the Specific Examples section below.
DETAILED DESCRIPTION OF THE INVENTION
Unless otherwise indicated, reference to a compound should be construed broadly to include pharmaceutically acceptable salts, prodrugs, tautomers, alternate solid forms, non-covalent complexes, and combinations thereof, of a chemical entity of the depicted structure or chemical name.
A pharmaceutically acceptable salt is any salt of the parent compound that is suitable for administration to an animal or human. A pharmaceutically acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt. A salt comprises one or more ionic forms of the compound, such as a conjugate acid or base, associated with one or more corresponding counter-ions. Salts can form from or incorporate one or more deprotonated acidic groups (e.g. carboxylic acids), one or more protonated basic groups (e.g. amines), or both (e.g. zwitterions).
A prodrug is a compound which is converted to a therapeutically active compound after administration. For example, conversion may occur by hydrolysis of an ester group or some other biologically labile group. Prodrug preparation is well known in the art. For example, "Prodrugs and Drug Delivery Systems," which is a chapter in Richard B. Silverman, Organic Chemistry of Drug Design and Drug Action, 2d Ed., Elsevier Academic Press: Amsterdam, 2004, pp. 496-557, provides further detail on the subject. Tautomers are isomers that are in rapid equilibrium with one another. For example, tautomers may be related by transfer of a proton, hydrogen atom, or hydride ion. Unless stereochemistry is explicitly depicted, a structure is intended to include every possible stereoisomer, both pure or in any possible mixture.
Alternate solid forms are different solid forms than those that may result from practicing the procedures described herein. For example, alternate solid forms may be polymorphs, different kinds of amorphous solid forms, glasses, and the like.
Non-covalent complexes are complexes that may form between the compound and one or more additional chemical species that do not involve a covalent bonding interaction between the compound and the additional chemical species. They may or may not have a specific ratio between the compound and the additional chemical species. Examples might include solvates, hydrates, charge transfer complexes, and the like.
In the novel compounds of this invention R3 and R4 may be independently selected from the group consisting of hydrogen, straight or branched chain alkyl having 1 to 12 carbons, cycloalkyl having 3 to 6 carbons, alkenyl having 2 to 6 carbons and 1 or 2 double bonds, alkynyl having 2 to 6 carbons and 1 or 2 triple bonds, aryl, preferably a carbocyclic aryl group having from 6 to 14 carbon atoms or a heterocyclic aryl group having from 2 to 14 carbon atoms and from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, halo, e.g. fluoro or chloro, Ci to C^ haloalkyl, e.g. trifluoromethyl, hydroxyl, Ci to C12 alkoxy, Ci to C12 alkylcarbonyl, formyl, oxycarbonyl, carboxy, Ci to Ci2 alkyl carboxylate, Ci to Ci2 alkyl amide, aminocarbonyl, amino, cyano, diazo, nitro, thio, sulfoxyl, or sulfonyl groups. R1 and R2 are aryl groups which may be any carbocyclic aryl or heterocyclic aryl group including but not limited to benzene, pyridine, pyrazine, pyridazine, pyrimidine, triazine, thiophene, furan, thiazole, thiadiazole, isothiazole, oxazole,oxadiazole, isooxazole, naphthalene, quinoline, tetralin, chroman, thiochroman, tetrahydroquinoline, dihydronaphthalene, tetrahydronaphthalen, chromene, thiochromene, dihydroquinoline, indan, dihydrobenzofuran, dihydrobenzothiophene, indene, benzofuran, benzothiophene, coumarin and coumarinone. Such aryl groups can be bonded to the above moiety at any position. Such aryl group may itself be substituted with any common organic functional group including but not limited to alkyl, alkenyl, alkynyl, aryl, halo, haloalkyl, hydroxyl, alkoxyl, alkylcarbonyl, formyl, oxycarbonyl, carboxyl, alkyl carboxylate, alkyl amide, aminocarbonyl, amino, cyano, diazo, nitro, thio, sulfoxyl, or sulfonyl groups.
Preferably, the carbocyclic aryl group will comprise from 6 to 14 carbon atoms, e.g. from 6 to 10 carbon atoms. Preferably the heterocyclic aryl group will comprise from 2 to 14 carbon atoms and one or more, e.g. from 1 to 3 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
Preferably, Rl is selected from the groups consisting of phenyl and substituted derivatives thereof;
R2 is selected, preferably from the group consisting of phenyl, furanyl, thienyl, pyridyl, pyranyl and substituted derivatives thereof;
R is selected from the group consisting of H and lower alkyl;
R4 is selected from the group consisting of H and lower alkyl; and a is 0 or an integer of from 1 to 3.
More preferably, R3 is H.
In this more preferred embodiment of the invention,
R1 is represented, preferably, by the general formula
wherein R5 is selected from the group consisting of H, alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g.chloro, and loweralkylthio.
In said compounds, preferably, R2 is selected from the group consisting of furanyl, thienyl, pyridyl and pyranyl or R 2 is
represented by the general formula
wherein R5 is selected from the group consisting of H, alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g. chloro, and loweralkylthio .
In one aspect of this invention X and Y are CR3 and Z is N. In another aspect of this invention, the compounds have a side chain which is terminated with carboxylic acid or carboxylic ester group, i.e. b is 0, c is 1, xis 1, y is 1 and z is 0.
Preferably, in said carboxylic acid or ester terminated compounds a is 0 and more preferably R4 is alkyl.
In another aspect of the invention R1 is a carbocyclic aryl having from 6 to 10 carbon atoms which may be substituted with an alkyl or halo alkyl group.
Preferably, R1 is phenyl which may be substituted with an alkyl or haloalkyl group.
In still another aspect of the invention R2 is a carbocyclic aryl having from 6 to 10 carbon atoms which may be substituted with an alkyl or haloalkyl group or R2 is pyridyl.
Preferably said alkyl group is a lower alkyl radical and said haloalkyl group is trifluoromethy 1.
In these phosphonic acid terminated compounds, preferably R3 is H, and
Furthermore, in said compounds, preferably c is 1, 2 or 3 and a is 1.
Finally, in said phosphonic acid-terminated compounds most preferably Z is N, X and Y are CR3, W is NR3, R2 is phenyl and R5 is selected from the group consisting of H and methyl or R2 is pyridyl and R5 is ethyl
In another aspect of the present invention d is 0 and therefore the compounds have a side chain which terminates in a carbon-oxygen radical such as a carboxylic acid, an ester thereof, an ether, an alcohol, or an alkyl carboxy group. In these carbon-oxygen terminated compounds, R1 may be represented by the general formula
wherein R5 is selected from the group consisting of H, alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g. chloro, and loweralkylthio
Furthermore R2 may also be represented by the general formula
wherein R5 is selected from the group consisting of H, lower alkyl, trifluoromethyl, trifluoromethyloxy, halo, e. g. chloro, and loweralkylthio or R2 is selected from the group consisting of furanyl, thienyl, pyridyl and pyranyl.
In such compounds, preferably R3 is H and more preferably, a is 1.
More preferably, in said compounds x is 1 , z is 0 and R4 is selected from the group consisting of H, methyl and ethyl.
Finally, in the carbon-oxygen compounds of this invention preferably is Z is N, X and Y are CR3, R2 is pyridyl, R4 is selected from the group consisting of methyl and ethyl and R5 is selected from the group consisting of H, methyl, ethyl, propyl and trifluoromethyl, or X, Y and Z are N, R4 is selected from the group consisting of methyl and ethyl and R5 is selected from the group consisting of H, methyl, ethyl, propyl and trifluoromethyl, or
X and Z are N and Y is CR
Unless otherwise indicated, the following terms as used throughout this specification have the following meanings:
"Me" refers to methyl.
"Et" refers to ethyl.
"tBu" refers to t-butyl.
"iPr" refers to i-propyl.
"Ph" refers to phenyl.
"Pharmaceutically acceptable salt" refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p- toluenesulfonic acid, salicylic acid and the like.
"Alkyl" refers to a straight-chain, branched or cyclic saturated aliphatic hydrocarbon. Preferably, the alkyl group has 1 to 12 carbons. More preferably, it is a lower alkyl of from 1 to 7 carbons, most preferably 1 to 4 carbons. Typical alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl and the like. The alkyl group may be optionally substituted with one or more substituents are selected from the group consisting of hydroxyl, cyano, alkoxy, .= O, .= S, NO2, halogen, dimethyl amino, and SH.
"Alkenyl" refers to a straight-chain, branched or cyclic unsaturated hydrocarbon group containing at least one carbon—carbon double bond. Preferably, the alkenyl group has 2 to 12 carbons. More preferably it is a lower alkenyl of from 2 to 7 carbons, most preferably 2 to 4 carbons. The alkenyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, O, S, NO2, halogen, dimethyl amino, and SH.
"Alkynyl" refers to a straight-chain, branched or cyclic unsaturated hydrocarbon containing at least one carbon—carbon triple bond. Preferably, the alkynyl group has 2 to 12 carbons. More preferably it is a lower alkynyl of from 2 to 7 carbons, most preferably 1 to 4 carbons. The alkynyl group may be optionally substituted with one or more substituents selected from the group consisting of hydroxyl, cyano, alkoxy, O, S, NO2, halogen, dimethyl amino, and SH.
"Alkoxyl" refers to an "O-alkyl" group.
"Aryl" refers to an aromatic group which has at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups. The aryl group may be optionally substituted with one or more substituents selected from the group consisting of halogen, trihalomethyl, hydroxyl, SH, OH, NO2, amine, thioether, cyano, alkoxy, alkyl, and amino.
"Alkaryl" refers to an alkyl that is covalently joined to an aryl group. Preferably, the alkyl is a lower alkyl. "Carbocyclic aryl" refers to an aryl group wherein the ring atoms are carbon.
"Heterocyclic aryl" refers to an aryl group having from 1 to 3 heteroatoms as ring atoms, the remainder of the ring atoms being carbon. Heteroatoms include oxygen, sulfur, and nitrogen.
"Hydrocarbyl" refers to a hydrocarbon radical having only carbon and hydrogen atoms. Preferably, the hydrocarbyl radical has from 1 to 20 carbon atoms, more preferably from 1 to 12 carbon atoms and most preferably from 1 to 7 carbon atoms.
"Substituted hydrocarbyl" refers to a hydrocarbyl radical wherein one or more, but not all, of the hydrogen and/or the carbon atoms are replaced by a halogen, nitrogen, oxygen, sulfur or phosphorus atom or a radical including a halogen, nitrogen, oxygen, sulfur or phosphorus atom, e.g. fluoro, chloro, cyano, nitro, hydroxyl, phosphate, thiol, etc.
"Amide" refers to -C(O)-NH-R', wherein R' is alkyl, aryl, alkylaryl or hydrogen.
"Thioamide" refers to -C(S)-NH-R, wherein R is alkyl, aryl, alkylaryl or hydrogen.
"Amine" refers to a — N(R")R" group, wherein R" and R'" are independently selected from the group consisting of alkyl, aryl, and alkylaryl.
"Thioether" refers to — S— R", wherein R" is alkyl, aryl, or alkylaryl.
"Sulfonyl" refers to -S(O)2 -R"", where R"" is aryl, C(CN)=C-aryl, CH2 CN, alkyaryl, sulfonamide, NH-alkyl, NH-alkylaryl, or NH-aryl. SPECIFIC EXAMPLES
Specific compounds of the invention and their activity at the sphingosine-1 - phosphate receptors are reported in Table I, below.
Compounds were also assessed for their ability to activate or block activation of the human S1P3 receptor in T24 cells stably expressing the human S1P3 receptor. Ten thousand cells/well were plated into 384-well poly-D-lysine coated plates one day prior to use. The growth media for the S1P3 receptor expressing cell line was McCoy's 5 A medium supplemented with 10% charcoal-treated fetal bovine serum (FBS), 1% antibiotic-antimycotic and 400 μg/ml geneticin. On the day of the experiment, the cells were washed twice with Hank's Balanced Salt Solution supplemented with 20 mM HEPES (HBSS/Hepes buffer). The cells were then dye loaded with 2 uM Fluo-4 diluted in the HBSS/Hepes buffer with 1.25 mM Probenecid and incubated at 370C for 40 minutes. Extracellular dye was removed by washing the cell plates four times prior to placing the plates in the FLIPR (Fluorometric Imaging Plate Reader, Molecular Devices). Ligands were diluted in HBSS/Hepes buffer and prepared in 384-well microplates. The positive control, Sphingosine-1 -Phosphate (SlP), was diluted in HBSS/Hepes buffer with 4 mg/ml fatty acid free bovine serum albumin. The FLIPR transferred 12.5 μl from the ligand microplate to the cell plate and took fluorescent measurements for 75 seconds, taking readings every second, and then for 2.5 minutes, taking readings every 10 seconds. Drugs were tested over the concentration range of 0.61 nM to 10,000 nM. Data for Ca+2 responses were obtained in arbitrary fluorescence units and not translated into Ca+2 concentrations. IC50 values were determined through a linear regression analysis using the Levenburg Marquardt algorithm. In Table 1 , NA is defined as "Not Active," ND is defined as "Not Determined," % efficacy is defined as "percent of receptor activity induced by a test compound at the highest dose test (10 μM) relative to the receptor activity induced by 5 nM sphingosine-1- phosphate.," and % inhibition is defined as "percent of receptor activity induced by 5 nM sphingosine-1 -phosphate that is inhibited by a test compound at the highest dose tested (10 μM)."
Table 1
Example
Structure S1P3 EC50 Number (% efficacy)
Table 1
Example
Structure S1P3 EC50 Number (% efficacy)
Table 1
Example
Structure S1P3 EC50 Number (% efficacy)
53 cr NA Table 1
Example
Structure S1P3 EC50 Number (% efficacy)
Table 1
Example
Structure S1P3 EC50 Number (% efficacy)
Table 1
Example
Structure S1P3 EC50 Number (% efficacy)
As a result of the above activity of the compounds utilized in the method of the present invention, it is clear that such compounds may be used in treating the following diseases and conditions for the following reasons. Pain
SlP increases capsaicin responsiveness of DRG neurons SlP pathway, S1P3, SlPl deregulated in multiple pain models (EHT/AGN) Glaucoma
S IP 1/3 subtypes expressed in primary HTM cells SlP decreases outflow facility >30% in perfused porcine eyes (See IOVS 45, 2263; 2004)
Altered paracellular permeability Dry Eye/Immunology Induces lymphocyte sequestration without affecting T cell proliferation
Angiogenesis disorders siRNA knockdown of SlPl and S1P3 inhibits angiogenesis S IP 1/3 subtypes expressed in VEC promote VEC migration promote barrier assembly and integrity
Cardiovascular (S1P3)
S1P3 "knock out" mice lack SlP induced COPD S1P3 agonism is dose limiting effect of FTY720 Wound Healing S IP is released from activated platelets
The invention is further illustrated by the following examples which are illustrative of a specific mode of practicing the invention and are not intended as limiting the scope of the claims.
The foregoing description details specific methods and compositions that can be employed to practice the present invention, and represents the best mode contemplated. Thus, however detailed the foregoing may appear in text, it should not be construed as limiting the overall scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims. Unless otherwise indicated, the following Chemical Abbreviations are used in the examples:
NH4Cl: ammonium chloride CHCl3 : chloroform Et2O: diethyl ether DIBAL-H: diisobutylaluminum hydride
DME : 1 ,2-dimethoxyethane
DMF: Λ/,Λ/-dimethylformamide
DMSO: dimethylsulfoxide EtOH: ethanol
EtOAc: ethyl acetate
HCl: hydrogen chloride or hydrochloric acid
NH2OH-HCl: hydroxylamine hydrochloride
MeI: iodomethane i-PrOH: isopropanol
MgSO4: magnesium sulfate
MeOH: methanol
NH2OMe-HCl: methoxylamine hydrochloride
CH2Cl2: methylene chloride KOH: potassium hydroxide
K2COs: potassium carbonate
PTLC: preparative thin layer chromatography
MPLC: medium pressure liquid chromatography
RuC12(PPh3)4: Na: sodium NaOEt: sodium ethoxide
NaOH: sodium hydroxide
Na2SO4: sodium sulfate
NaHCO3 : sodium bicarbonate
NaBH4: sodium borohydride NaBH3CN: sodium cyanoborohydride
NaH: sodium hydride
H2SO4: sulfuric acid
Bu4NOH: tetrabutylammonium hydroxide
THF: tetrahydrofuran Pd(PPlIs)4: palladium tetrakis(tripenylphosphine)
TMSI: iodotrimethylsilane
All other chemicals were purchased from Aldrich Chemical Company, and they were used as provided.
Scheme 1
R =Me I R = Me R =Et 2 R = Et R = H-Pr 3 R = H-Pr R = CF3 4 R = CF3 R = W-C9H19 5 R = H-C9H19
6 R =Me 11 R1 = H 17 R2 =Me 7 R = Et 12 R1 =Me 18 R2 = Et 8 R = H-Pr 13 R1 = Et 19 R2 = CF3 9 R = CF3 14 R1 = H-Pr 20 R2 = H-C9H19 10 R = W-C9H19 15 R1 = CF3
30 R1 = H, R2 = R3 = H 21 R1 = R3 = H 27 R2 = Me
31 R1 = Me, R2 = R3 = H 22 R1 =Me, R3 = H 28 R2 = Et
32 R1 = Et , R2 = R3 = H 23 R1 = Et, R3 = H 29 R2 = CF3
33 R1 = H-Pr, R2 = R3 = H 24 R1 = H-Pr, R3 = H
34 R1 = CF3 , R2 = R3 = H 25 R1 = CF3, R3 = H
35 R1 =R3 = H , R2= CF3 26 R1 = Et. R3 =Me
36 R1 = Et , R2 =H, R3 = Me
(a) B(OiPr) 3, Pd(PPh3)4, DME, THF, 90 0C, 2 hours, (b) RuCl2(PPH3) 3, PhIO, CH2Cl2, (c) ethyl oxalamidrazonate, ethanol, (d) i) pyrrolidine, CH3CHO, K2CO3, toluene, 11) CHC13, 720C, (e) c H2SO4, MeOH, 70 0C
Example 1 l-(2-p-Tolylethynyl)benzene (Compound 1). General Procedure A. To a solution of lithium phenylacetylide (15.2 ml, 15.2 mmol) in DME (20 ml) under Argon at -78 0C was added triisopropoxylborane (3.5 ml, 15.2 mmol). The mixture was stirred at -78 0C for 1.5 hours. A solution of l-bromo-4-methylbenzene (2 g, 11.7 mmol) in DME/THF (10 ml/1 OmI) was degassed with dry argon, Pd(PPh3)4 (405 mg, 0.35 mmol) was added and the solution was degassed for another 5 min. The degassed solution was cannulated into the first solution, and the mixture was heated under argon at 85 0C for 2 hours. The mixture was cooled to room temperature, and it was diluted with ethyl acetate, and washed with water. The separated organic layer was washed with water and brine, and dried over MgSO4. The filtered solvent was concentrated in vacuo, and the residue was purified by column chromatography (silica, 5% ethyl acetate in hexane) to give the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3): δ 2.37 (s, 3 H), 7.16 (d, J= 8.50 Hz, 2 H), 7.29 - 7.38 (m, 3 H), 7.43 (d, J= 7.92 Hz, 2 H), 7.48 - 7.56 (m, 2 H). Example 2 l-(2-(4-Ethylphenyl)ethynyl)benzene (Compound 2) Following General Procedure A, lithium phenylacetylide (14.0 ml, 14.1 mmol), triisopropoxylborane (3.2 ml, 14.1 mmol), l-bromo-4-ethylbenzene (2 g, 10.8 mmol) and Pd(PPh3)4 (375 mg, 0.32 mmol) in DME (30ml) and THF (10 ml) were reacted to obtain the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3): δ 1.24 (t, J= 7.62 Hz, 3 H), 2.66 (q, J= 7.62 Hz, 2 H), 7.18 (d, J= 8.21 Hz, 2 H), 7.28 - 7.39 (m, 3 H), 7.45 (d, J= 8.21 Hz, 2 H), 7.49 - 7.56 (m, 2 H).
Example 3 l-(2-(4-n-Proylphenyl)ethynyl)benzene (Compound 3) Following General
Procedure A, lithium phenylacetylide (13.0 ml, 13.1 mmol), triisopropoxylborane (3.0 ml, 13.1 mmol), l-bromo-4-n-propylbenzene (2 g, 10.1 mmol) and Pd(PPh3 )4 (348 mg, 0.30 mmol) in DME (30 ml) and THF (10 ml) were reacted to obtain the title compound as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 0.94 (t, J= 7.33 Hz, 17 H), 1.57 - 1.73 (m, 2 H), 2.57 - 2.62 (m, 2 H), 7.16 (d, J= 8.50 Hz, 2 H), 7.29 - 7.40 (m, J= 2.05 Hz, 3 H), 7.44 (d, J= 8.50 Hz, 2 H), 7.49 - 7.55 (m, 2 H).
Example 4 l-(2-(4-Trifluoromethylphenyl)ethynyl)benzene (Compound 4) Following General Procedure A, lithium phenylacetylide (17.3 ml, 17.3 mmol), triisopropoxylborane (4.0 ml, 17.3 mmol), l-bromo-4-trifluoromethyl-benzene (3 g, 13.3 mmol) and Pd(PPh3)4 (462 mg, 0.40 mmol) in DME (40 ml) and THF (15 ml) were reacted to obtain the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 7.31 - 7.42 (m, 3 H), 7.50 - 7.58 (m, 2 H), 7.57 - 7.68 (m, 4 H).
Example 5 l-(2-(4-n-Nonanylphenyl)ethynyl)benzene (Compound 5) Following General Procedure A, lithium phenylacetylide (12.4 ml, 12.4 mmol), triisopropoxylborane (2.8 ml, 12.4 mmol), l-bromo-4-n-nonanylbenzene (2.7 g, 9.5 mmol) and Pd(PPh3)4 (331 mg, 0.40 mmol) in DME (30 ml) and THF (10 ml) were reacted to obtain the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 0.88 (t, J= 7.04 Hz, 3 H), 1.17 - 1.38 (m, 12 H), 1.54 - 1.68 (m, 2 H), 2.55 - 2.65 (m, 2 H), 7.15 (d, J= 8.21 Hz, 2 H), 7.28 - 7.39 (m, 3 H), 7.44 (d, J= 8.21 Hz, 2 H), 7.48 - 7.56 (m, 2 H).
Example 6 l-Phenyl-2-p-tolylethane-l,2-dione (Compound 6). General Procedure B. To a suspension of iodosobenzene (2.5 g, 11.3 mmol) in CH2Cl2 (30 ml) was added RuCl2(PPh3)4 (45 mg, 0.04 mmol). A solution of 1 -(2-p-tolylethynyl)benzene (Compound 1, 835 mg, 4.3 mmol) in CH2Cl2 (10 ml) was cannulated into the suspension. The resulting mixture was stirred at room temperature overnight resulting in a homogeneous solution. The solvent was removed in vacuo, and the residue was purified by silica gel chromatography (10% ethyl acetate in hexane) to produce the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3) δ 2.44 (s, 3 H), 7.31 (d, J = 7.92 Hz, 2 H), 7.51 (t, J = 7.62 Hz, 2 H), 7.59 - 7.71 (m, 1 H), 7.87 (d, J= 8.21 Hz, 2 H), 7.92 - 8.00 (m, 2 H).
Example 7 l-(4-Ethyl-phenyl)-2-phenyl-ethane-l,2-dione (Compound 7). Following General Procedure B, iodosobenzene (1.5g, 6.7 mmol), RuCl2(PPhS)4 (21 mg, 0.02 mmol) and l-(2-(4-ethylphenyl)ethynyl)benzene (Compound 2, 360 mg, 1.8 mmol) in CH2Cl2 (30 ml) were reacted to produce the title compound as a yellow oil.
1U NMR (300 MHz, CDCl3) δ 1.26 (t, J= 7.62 Hz, 3 H), 2.73 (q, J= 7.62 Hz, 2 H), 7.34 (d, J= 8.50 Hz, 2 H), 7.45 - 7.56 (m, 2 H), 7.59 - 7.70 (m, 1 H), 7.90 (d, J = 8.21 Hz, 2 H), 7.93 - 8.01 (m, 2 H).
Example 8 l-(4-n-Propyl-phenyl)-2-phenyl-ethane-l,2-dione (Compound 8). Following General Procedure B, iodosobenzene (2.2 g, 10.0 mmol), RuCl2(PPhS)4 (38 mg, 0.04 mmol) and l-(2-(4-/?-propylphenyl)ethynyl)benzene (Compound 3, 860 mg, 3.9 mmol) in CH2Cl2 (50 ml) were reacted to produce the title compound as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 0.95 (t, J= 7.62 Hz, 3 H), 1.58 - 1.76 (m, 2 H), 2.60 -2.69 (m, 2 H), 7.31 (d, J= 8.21 Hz, 2 H), 7.46 - 7.56 (m, 2 H), 7.61 - 7.70 (m, 1 H), 7.89 (d, J= 8.21 Hz, 2 H), 7.94 - 8.01 (m, 2 H).
Example 9 l-(4-Trifluoromethyl -phenyl)-2-phenyl-ethane-l,2-dione (Compound 9). Following General Procedure B, iodosobenzene (5.5g, 24.3 mmol), RuCl2(PPh3)4 (96 mg, 0.10 mmol) and l-(2-(4-trifluoromethyl phenyl)ethynyl)benzene (Compound 4, 1.9 g, 8.1 mmol) in CH2Cl2 (100 ml) were reacted to produce the title compound as a yellow solid.
1U NMR (300 MHz, CDCl3) δ 7.49 - 7.59 (m, 2 H), 7.65 - 7.74 (m, 1 H), 7.79 (d, J = 8.21 Hz, 2 H), 7.94 - 8.02 (m, 2 H), 8.11 (d, J= 8.21 Hz, 2 H).
Example 10 l-(4-n-Nonanylphenyl)-2-phenylethane-l,2-dione (Compound 10). Following General Procedure B, iodosobenzene (744 mg, 3.39 mmol), RuCl2(PPh3 )4 (11 mg, 0.01 mmol) and l-(2-(4-/?-nonanylphenyl)ethynyl)benzene (Compound 5, 343 mg, 1.12 mmol) in CH2Cl2 (30 ml) were reacted to produce the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3) δ 0.87 (t, J= 6.74 Hz, 3 H), 1.14 - 1.40 (m, 12 H), 1.55 - 1.71 (m, 2 H), 7.48 - 7.53 (m, 2 H), 7.60 - 7.72 (m, 1 H), 7.88 (d, J= 8.21 Hz, 2 H), 7.94 - 8.02 (m, 2 H).
Example 11
Ethyl 5,6-Diphenyl-l,2,4-triazine-3-carboxylate (Compound 11). General Procedure C. A solution of ethyl oxalamidrazonate (Compound 37, 236 mg, 1.8 mmol) in ethanol (20 ml) was cannulated slowly into a stirring solution of benzil (500 mg, 2.4 mmol) in ethanol (20 ml) under argon at room temperature. After the addition was completed, the reaction was stirred at room temperature overnight (~16 hours). The mixture was then refluxed for 1 hour. The solvent was removed in vacuo, and the crude products was purified by column chromatography (silica gel, 20% ethyl acetate in hexane) to obtain the title compound as an oil.
1H NMR (300 MHz, acetone-*/*) δ 1.45 (t, J= 7.04 Hz, 3 H), 4.54 (q, J= 7.13 Hz,
2 H), 7.38 - 7.58 (m, 6 H), 7.61 - 7.72 (m, 4 H).
Example 12 and Example 17
Ethyl 6-Phenyl-5-p-tolyl-l,2,4-triazine-3-carboxylate (Compound 12), and Ethyl 5-Phenyl-6-p-tolyl-l,2,4-triazine-3-carboxylate (Compound 17).
Following General Procedure C, ethyl oxalamidrazonate (Compound 37, 121 mg, 0.9 mmol), l-phenyl-2-/?-tolylethane-l,2-dione (Compound 6, 268 mg, 1.2 mmol) in ethanol (10 ml) were reacted, and the products were separated by recrystalization from 5% ethyl acetate in hexane to produce Compound 12 and Compound 17 as yellow solids.
Compound 12: 1H NMR (300 MHz, CDCl3): δ 1.50 (t, J= 7.33 Hz, 3 H), 2.39 (s,
3 H), 4.61 (q, J= 7.04 Hz, 2 H), 7.19 (d, J= 7.92 Hz, 2 H), 7.32 - 7.49 (m, 3 H), 7.52 (d, J= 8.21 Hz, 2 H), 7.63 - 7.69 (m, 2 H). Compound 17: 1H NMR (300 MHz, CDCl3): δ 1.51 (t, J= 7.04 Hz, 3 H), 2.37 (s, 3 H), 4.61 (q, J= 7.04 Hz, 2 H), 7.15 (d, J= 7.92 Hz, 2 H), 7.35 - 7.51 (m, 3 H), 7.56 (d, J= 8.50 Hz, 2 H), 7.60 - 7.66 (m, 2 H).
Example 13 and Example 18 Ethyl 6-(4-Ethylphenyl)-5-phenyl -l,2,4-triazine-3-carboxylate (Compound 13), and Ethyl 5-(4-Ethylphenyl)-6-phenyl-l,2,4-triazine-3-carboxylate (Compound 18). Following General Procedure C, ethyl oxalamidrazonate (Compound 37, 117 mg, 0.9 mmol) and l-(4-Ethyl-phenyl)-2-phenyl-ethane-l,2- dione (Compound 7, 276 mg, 1.2 mmol) in ethanol (10 ml) were reacted, and the products were separated by recrystalization from 5% ethyl acetate in hexane to produce Compound 13 and Compound 18 as yellow solids.
Compound 13: 1H NMR (300 MHz, CDCl3): δ 1.26 (t, J= 7.81 Hz, 3 H), 1.51 (t, J = 7.32 Hz, 3 H), 2.69 (q, J= 7.81 Hz, 2 H), 4.61 (q, J= 7.32 Hz, 2 H), 7.23 (d, J = 7.32 Hz, 2 H), 7.35 - 7.38 (m, 2 H), 7.45 - 7.47 (m, 1 H), 7.56 (d, J= 8.30 Hz, 2 H), 7.67 (d, J= 7.81 Hz, 2 H).
Compound 18: 1H NMR (300 MHz, CDCl3): δ 1.23 (t, J= 7.81 Hz, 3 H), 1.51 (t, J= 7.32 Hz, 3 H), 2.67 (q, J= 7.81 Hz, 2 H), 4.62 (q, J= 7.32 Hz, 2 H), 7.19 (d, J = 8.79 Hz, 2 H), 7.39 - 7.42 (m, 2 H), 7.45 - 7.48 (m, 1 H), 7.59 (d, J= 8.30 Hz, 2 H), 7.65 (d, J= 8.30 Hz, 2 H). Example 14
Ethyl 5-Phenyl-6-(4-propylphenyl)-l,2,4-triazine-3-carboxylate (Compound 14). Following General Procedure C, ethyl oxalamidrazonate (Compound 37, 460 mg, 1.5 mmol) and l-(4-n-propylphenyl)-2-phenyl-ethane-l,2-dione (Compound 8, 588 mg, 2.3 mmol) in ethanol (40 ml) were reacted and the product was recrystalized from 5% ethyl acetate in hexane to produce the title compound as yellow solid. 1H NMR (300 MHz, CDCl3) δ 0.95 (t, J= 7.33 Hz, 3 H), 1.51 (t, J= 7.04 Hz, 3 H), 1.62 - 1.74 (m, 2 H), 2.55 - 2.63 (m, 2 H), 4.61 (q, J= 7.13 Hz, 2 H), 7.20 (d, J = 8.50 Hz, 2 H), 7.32 - 7.49 (m, 3 H), 7.50 - 7.57 (m, 2 H), 7.62 - 7.70 (m, 2 H).
Example 15 and Example 19 Ethyl 6-(4-Trifluoromethyl-phenyl)-5-phenyl -1,2,4— triazine-3-carboxylate (Compound 15), and Ethyl 5-(4-Trifluoromethylphenyl)-6-phenyl- 1,2,4— triazine-3-carboxylatate (Compound 19). Following General Procedure C, ethyl oxalamidrazonate (Compound 37, 1.2 g, 8.8 mmol) and l-(4-tirfluoromethyl- phenyl)-2-phenyl-ethane-l,2-dione (Compound 9, 1.6 g, 5.9 mmol) in ethanol (40 ml) were reacted, and the products were separated by recrystalization from 5% ethyl acetate in hexane to produce Compound 15 and Compound 19 as yellow solids.
Compound 15: 1H NMR (300 MHz, CDCl3) δ 1.52 (t, J= 7.18 Hz, 3 H), 4.63 (q, J = 7.04 Hz, 2 H), 7.38 - 7.54 (m, 3 H), 7.56 - 7.68 (m, 4 H), 7.78 (d, J= 8.21 Hz, 2 H).
Compound 19: 1H NMR (300 MHz, CDCl3) δ 1.52 (t, J = 7.18 Hz, 3 H), 4.63 (q, J= 7.13 Hz, 2 H), 7.35 - 7.54 (m, 3 H), 7.59 - 7.70 (m, 4 H), 7.73 - 7.81 (m, 2 H).
Example 16 and Example 20
Ethyl 6-(4-Nonylphenyl)-5-phenyl-l,2,4-triazine-3-carboxylate (Compound 16), and Ethyl 5-(4-Nonylphenyl)-6-phenyl-l,2,4-triazine-3-carboxylate (Compound 20). Following General Procedure C, ethyl oxalamidrazonate (Compound 37, 108 mg, 0.83 mmol) and l-(4-nonylphenyl)-2-phenylethane-l,2- dione (Compound 10, 252 mg, 0.75 mmol) in ethanol (10 ml) were reacted and the mixture purified by MPLC to isolate Compound 16 and Compound 20 as yellow oils.
Compound 16: 1H NMR (300 MHz, CDCl3): δ 0.88 (t, J= 7.04 Hz, 3 H), 1.18 - 1.39 (m, 12 H), 1.51 (t, J= 7.18 Hz, 3 H), 1.56 - 1.72 (m, 2 H), 2.58 - 2.70 (m, 2 H), 4.61 (q, J= 7.23 Hz, 2 H), 7.20 (d, J= 8.21 Hz, 2 H), 7.31 - 7.41 (m, 2 H), 7.33 - 7.40 (m, 1 H), 7.53 (d, J= 8.21 Hz, 2 H), 7.61 - 7.70 (m, 2 H).
Compound 20: 1U NMR (300 MHz, CDCl3): IH NMR (300 MHz, Solvent) δ 0.88 (t, J= 7.04 Hz, 3 H), 1.17 - 1.37 (m, 12 H), 1.52 (t, J= 7.04 Hz, 3 H), 1.55 - 1.66 (m, 2 H), 2.54 - 2.69 (m, 2 H), 4.62 (q, J= 7.04 Hz, 2 H), 7.16 (d, J= 8.21 Hz, 2 H), 7.33 - 7.53 (m, 3 H), 7.58 (d, J= 8.21 Hz, 2 H), 7.60 - 7.70 (m, 2 H).
Example 21
Ethyl 5,6-diphenylpyridine-2-carboxylate (Compound 21). General Procedure
D. Ethyl 5,6-diphenyl-l,2,4~triazine-3-carboxylate (Compound 11, 200 mg, 0.66 mmol) and crude 1-vinylpyrrolidine (Compound 38, 2 g) in CHCl3 (20 ml) was heated at 75 0C overnight under nitrogen. The solvent was removed in vacuo, and the residue was purified by silica gel column chromatography (20 % ethyl acetate in hexane) to yield the title compound as a light yellow solid.
1H NMR (300 MHz, CDCl3) δ 1.46 (t, J= 7.18 Hz, 3 H), 4.50 (q, J= 7.13 Hz, 2 H), 7.13 - 7.33 (m, 8 H), 7.35 - 7.44 (m, 2 H), 7.84 (d, J= 7.92 Hz, 1 H), 8.12 (d, J = 7.92 Hz, 1 H).
Example 22
Ethyl 6-Phenyl-5-p-tolyl-pyridine-2-carboxylate (Compound 22). Following General Procedure D, ethyl 5-phenyl-6-/?-tolyl-l,2,4— triazine-3-carboxylate (Compound 12, 177 mg, 0.56 mmol) and crude 1-vinylpyrrolidine (Compound 38, 730 mg) in CHCl3 (10 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 1.45 (t, J = 7.18 Hz, 3 H), 2.34 (s, 3 H), 4.49 (q, J = 7.04 Hz, 2 H), 7.05 - 7.11 (m, 4 H), 7.17 - 7.28 (m, 3 H), 7.36 - 7.44 (m, 2 H), 7.82 (d, J= 7.92 Hz, 1 H), 8.10 (d, J= 7.92 Hz, 1 H).
Example 23
Ethyl 5-(4-Ethyl-phenyl)-6-phenyl-pyridine-2-carboxylate (Compound 23).
Following General Procedure D, ethyl 6-(4-ethyl-phenyl)-5-phenyl-l,2,4-triazine- 3-carboxylate (Compound 13, 105 mg, 0.30 mmol) and crude 1-vinylpyrrolidine (Compound 38, 2 g) in CHCI3 (10 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 1.19 (t, J= 7.62 Hz, 3 H), 1.45 (t, J= 7.04 Hz, 3 H), 2.58 (q, J= 7.62 Hz, 2 H), 4.47 (q, J= 7.04 Hz, 2 H), 7.09 - 7.16 (m, 4 H), 7.22 - 7.30 (m, 3 H), 7.36 - 7.42 (m, 2 H), 7.83 (d, J= 7.92 Hz, 1 H), 8.10 (d, J= 7.91 Hz, 1 H).
Example 24
Ethyl 6-Phenyl-5-(4-propylphenyl)-pyridine-2-carboxylate (Compound 24). Following General Procedure D, ethyl 5-phenyl-6-(4-propyl-phenyl)- 1,2,4— triazine-3-carboxylate (Compound 14), (153 mg, 0.46 mmol) and crude 1- vinylpyrrolidine (Compound 38, 2 g) in CHCl3 (10 ml) were reacted to produce the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3) δ 0.94 (t, J= 7.33 Hz, 3 H), 1.45 (t, J= 7.04 Hz, 3 H), 1.56 - 1.72 (m, 2 H), 2.55 - 2.62 (m, 2 H), 4.49 (q, J= 7.23 Hz, 2 H), 7.09 (s, 4 H), 7.20 - 7.30 (m, 3 H), 7.36 - 7.45 (m, 2 H), 7.84 (d, J= 7.92 Hz, 1 H), 8.11 (d, J = 7.92 Hz, 1 H).
Example 25
Ethyl 6-Phenyl-5-(4-trifluoromethylphenyl)-pyridine-2-carboxylate (Compound 25). Following General Procedure D, ethyl 6-(4- tirfluoromethylphenyl)-5 -phenyl -l,2,4-triazine-3-carboxylate (Compound 15), (378 mg, 1.01 mmol) and crude 1-vinylpyrrolidine (Compound 38, 780 mg) in CHCl3 (10 ml) were reacted to produce the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3) δ 1.47 (t, J= 7.18 Hz, 3 H), 4.52 (q, J= 7.04 Hz, 2 H), 7.15 - 7.22 (m, 2 H), 7.30 - 7.36 (m, 3 H), 7.47 - 7.58 (m, 4 H), 8.18 (d, J = 7.92 Hz, 1 H).
Example 26 Ethyl 5-(4-Ethylphenyl)-3-methyl-6-phenyl-pyridine-2-carboxylate (Compound 26). Following General Procedure D, ethyl 6-(4-ethylphenyl)-5- phenyl-1,2,4— triazine-3-carboxylate (Compound 13, 200 mg, 0.60 mmol) and crude 1-propenyl-pyrrolidine (Compound 39, 2 g) in CHCI3 (10 ml) were reacted to produce the title compound as a yellow oil.
1H NMR (500 MHz, CDCl3) δ 1.23 (t, J= 7.81 Hz, 3 H), 1.45 (t, J= 7.08 Hz, 3 H), 2.56 - 2.69 (m, 5 H), 4.47 (q, J= 7.08 Hz, 2 H), 7.01 - 7.15 (m, 4 H), 7.16 - 7.30 (m, 3 H), 7.35 - 7.42 (m, 2 H), 7.60 (s, 1 H).
Example 27 Ethyl 5-Phenyl-6-p-tolyl-pyridine-2-carboxylate (Compound 27). Following General Procedure D, ethyl 6-phenyl-5-/?-tolyl-l,2,4-triazine-3-carboxylate (Compound 17, 361 mg, 1.13 mmol) and crude 1-vinylpyrrolidine (Compound 38, 806 mg) in CHCl3 (10 ml) were reacted to produce the title compound as a yellow oil. 1H NMR (300 MHz, CDCl3) δ 1.45 (t, J= 7.18 Hz, 3 H), 2.30 (s, 3 H), 4.49 (q, J = 7.04 Hz, 2 H), 7.05 (d J= 7.92 Hz, 2 H), 7.14 - 7.24 (m, 2 H), 7.27 - 7.33 (m, 5 H), 7.82 (d, J= 7.92 Hz, 1 H), 8.09 (d, J= 7.91 Hz, 1 H).
Example 28
Ethyl 6-(4-Ethylphenyl)-5-phenyl-pyridine-2-carboxylate (Compound 28). Following General Procedure D, ethyl 5-(4-ethylphenyl)-6-phenyl-l,2,4-triazine-3- carboxylate (Compound 18, 245 mg, 0.74 mmol) and crude 1-vinylpyrrolidine (Compound 38, 572 mg) in CHCl3 (10 ml) were reacted to produce the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3) δ 1.19 (t, J= 7.62 Hz, 3 H), 1.45 (t, J= 7.18 Hz, 3 H), 2.60 (q, J= 7.62 Hz, 2 H), 4.49 (q, J= 7.04 Hz, 2 H), 7.06 (d, J= 7.92 Hz, 2 H), 7.27 - 7.36 (m, 5 H), 7.82 (d, J= 7.92 Hz, 1 H), 8.09 (d, J= 7.91 Hz, 1 H).
Example 29 Ethyl 5-Phenyl-6-(4-trifluoromethyl-phenyl)-pyridine-2-carboxylate (Compound 29). Following General Procedure D, ethyl 5-(4- trifluoromethylphenyl)-6-phenyl-l,2,4~triazine-3-carboxylate (Compound 19, 1 g, 2.68 mmol) and crude 1-vinylpyrrolidine (Compound 38, 1.4 g) in CHCI3 (20 ml) were reacted to produce the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3) δ 1.46 (t, J= 7.18 Hz, 12 H), 4.51 (q, J= 7.23 Hz, 2 H), 7.21 - 7.42 (m, 5 H), 7.85 (d, J= 7.92 Hz, 1 H), 8.15 (d, J= 8.21 Hz, 1 H).
Example 30
Methyl 5,6-diphenylpyridine-2-carboxylate (Compound 30). General Procedure E. A solution of ethyl 5,6-diphenylpyridine-2-carboxylate (Compound 21, 30 mg, 0.1 mmol) and cone. H2SO4 (3 drops) in MeOH (5 ml) was heated at 50 0C overnight. The mixture was diluted with water, and the products were extracted with ethyl acetate. The organic layer was washed with water and brine, and dried over Na2SO4. The filtered solvent was concentrated in vacuo and the residue was purified by column chromatography (20 % ethyl acetate in hexane) to obtain the title compound as a yellow solid.
1H NMR (500 MHz, CDCl3) δ 4.02 (s, 3 H), 7.15 - 7.31 (m, 8 H), 7.38 (d, J= 7.81 Hz, 2 H), 7.86 (d, J= 8.30 Hz, 1 H), 8.15 (d, J= 7.81 Hz, I H).
Example 31 Methyl ό-Phenyl-S-p-tolyl-pyridine^-carboxylate (Compound 31).
Following General Procedure E, ethyl 6-phenyl-5-/?-tolyl-pyridine-2-carboxylate (Compound 22, 70 mg, 0.22 mmol) and cone. H2SO4 (3 drops) in MeOH (3 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 2.34 (s, 3 H), 4.01 (s, 3 H), 7.05 - 7.11 (m, 4 H), 7.19 - 7.30 (m, 3 H), 7.35 - 7.44 (m, 2 H), 7.84 (d, J= 7.92 Hz, 1 H), 8.13 (d, J = 7.92 Hz, 1 H).
Example 32
Methyl 5-(4-Ethylphenyl)-6-phenyl-pyridine-2-carboxylate (Compound 32). Following General Procedure E, ethyl 5-(4-ethylphenyl)- 6-phenylpyridine-2- carboxylate (Compound 23, 45 mg, 0.15 mmol) and cone. H2SO4 (3 drops) in MeOH (3 ml) were reacted to produce title compound as a yellow solid.
1U NMR (300 MHz, CDCl3) δ 1.23 (t, J= 7.62 Hz, 3 H), 2.64 (q, J= 7.62 Hz, 2 H), 4.02 (s, 3 H), 7.05 - 7.16 (m, 4 H), 7.19 - 7.29 (m, 3 H), 7.34 - 7.44 (m, 2 H), 7.84 (d, J= 7.92 Hz, 1 H), 8.13 (d, J= 7.92 Hz, 1 H).
Example 33
Methyl 6-Phenyl-5-(4-propylphenyl)-pyridine-2-carboxylate (Compound 33).
Following General Procedure E, ethyl 6-phenyl-5-(4-propylphenyl)-pyridine-2- carboxylate (Compound 24, 67 mg, 0.19 mmol) and cone. H2SO4 (3 drops) in MeOH (3 ml) were reacted to produce the title compound as a white solid.
1H NMR (300 MHz, CDCl3) δ 0.93 (t, J= 7.33 Hz, 3 H), 1.56 - 1.71 (m, 2 H), 2.51 - 2.63 (m, 2 H), 4.02 (s, 3 H), 7.01 - 7.13 (m, 4 H), 7.16 - 7.31 (m, 3 H), 7.34 - 7.43 (m, 2 H), 7.85 (d, J= 7.92 Hz, 1 H), 8.14 (d, J= 7.92 Hz, 1 H). Example 34
Methyl 6-Phenyl-5-(4-trifluoromethylphenyl)-pyridine-2-carboxylate (Compound 34).
Following General Procedure E, ethyl 6-phenyl-5-(4-trifluoromethylphenyl)- pyridine-2-carboxylate (Compound 25, 110 mg, 0.29 mmol) and cone. H2SO4 (5 drops) in MeOH (5 ml) were reacted to produce the title compound as a white solid.
1H NMR (300 MHz, CDCl3) δ 4.03 (s, 3 H), 7.08 - 7.22 (m, 3 H), 7.29 - 7.37 (m, 2 H), 7.51 (s, 4 H), 7.90 (d, J= 7.92 Hz, 1 H), 8.20 (d, J= 7.92 Hz, 1 H).
Example 35 Methyl 5-Phenyl-6-(4-trifluoromethylphenyl)-pyridine-2-carboxylate (Compound 35). Following General Procedure E, ethyl 5-phenyl-6-(4- trifluoromethylphenyl)-pyridine-2-carboxylate (Compound 29, 103 mg, 0.28 mmol) and cone. H2SO4 (5 drops) in MeOH (5 ml) were reacted to produce the title compound as a white solid.
1H NMR (300 MHz, CDCl3) δ 4.03 (s, 3 H), 7.21 - 7.40 (m, 7 H), 7.55 (d, J= 8.50 Hz, 2 H), 7.86 (d, J= 7.92 Hz, 1 H), 8.18 (d, J= 7.92 Hz, I H). Example 36
Methyl 5-(4-Ethylphenyl)-3-methyl-6-phenylpyridine-2-carboxylate (Compound 36). Following General Procedure E, ethyl 5-(4-ethylphenyl)-3- methyl-6-phenylpyridine-2-carboxylate (Compound 26, 29 mg, 0.08 mmol) and cone. H2SO4 (3 drops) in MeOH (5 ml) were reacted to produce the title compound as an oil.
1H NMR (500 MHz5CDCl3) δ 1.23 (t, J= 7.57 Hz, 3 H), 2.58 - 2.68 (m, 5 H), 3.99 (s, 3 H), 7.05 - 7.13 (m, 4 H), 7.18 - 7.25 (m, 3 H), 7.34 - 7.40 (m, 2 H), 7.61 (s, 1 H).
Scheme 2
37
R ^N . 9 K2CO3 f1
L) RAH -^≡^ rΛ
R = Me, Et 38, R = H
39, R = Me
Example 37
Ethyl oxalamidrazonate (Compound 37). A solution of anhydrous hydrazine (0.5 ml, 15.0 mmol) in ethanol (5 ml) was added dropwise to a stirred solution of ethyl thiooxamate (2 g, 15.0 mmol) in ethanol (45 ml) under argon at room temperature. The mixture was stirred at room temperature for 1 hour, and the solvent was removed in vacuo and dried under high vacuum to get a white solid which was maintained in argon atmosphere after drying. The white solid was used in the next step without further purification.
Example 38 1-vinylpyrrolidine (Compound 38). General Procedure F. To a suspension of K2CO3 (3.8 g, 28.1 mmol) and pyrrolidine (1 g, 14.0 mmol) in toluene (10 ml) was added acetylaldehyde under argon at 0 0C. The mixture was stirred at room temperature overnight. After filtration, the filtrate was concentrated in vacuo to yield a crude oil which was used in the next reaction without further purification. Example 39
1-Propenylpyrrolidine (Compound 39). Following General Procedure F, K2CO3 (3.8 g, 28.1 mmol), pyrrolidine (1 g, 14.0 mmol) and propionaldehyde (1.6 g, 28.1 mmol) in toluene (10 ml) were reacted to produce the title compound as a brown oil. Example 40
(£)-3-(4-ethylphenyl)prop-2-en-l-ol (Compound 40). General Procedure G. A solution of ethyl chloro formate (1.1 ml, 11.4 mmol) in THF (5 ml) was added to a solution of 4-ethylcinnamic acid (2 g, 11.4 mmol) and triethylamine (1.6 ml, 11.4 mmol) in THF (50 ml) at -5 0C to -10 0C, and the solution was stirred for 30 min. The resulting white precipitate was filtered off, rinsed with THF (10 ml), and the combined filtrates were added to a solution OfNaBH4 (945 mg, 24.9 mmol) in H2O (20 ml) slowly in order to maintain an internal temperature of 10 0C to 15 0C. After the addition was completed, the reaction was stirred at room temperature for 4 hours, and then it was made acidic with HCl (20 %). The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with NaHCO3 (aq), and water, and brine, and dried over Na2SO4. The filtered solution was concentrated in vacuo, and the residue was purified by column chromatography (20 % ethyl acetate in hexane) to yield a white solid.
1H NMR (500 MHz, CDCl3): δ ppm 1.23 (t, J= 7.32 Hz, 3 H), 2.64 (q, J= 7.32 Hz, 2 H), 4.31 (s, 2 H), 6.30 - 6.39 (m, I H), 6.61 (d, J=16.11 Hz, I H), 7.16 (d, J = 8.30 Hz, 2 H), 7.32 (d, J= 8.30 Hz, 2 H).
Scheme 3
R = Et 40 R = Et 42 R = Et R = Me 41 R = Me 43 R = Me
44 R = Et 46 R = Et
45 R = Me 47 R = Me
48 R = 4-(trifluoromethyl)phenyl 51 R = 4-(trifluoromethyl)phenyl 49 R = 4-pyridyl 52 R = 4-pyridyl 50 R = 2-pyridyl 53 R = 2-pyridyl
(a) i) Ethyl chloroformate, TEA, THF, ii) NaBH4, H2O, THF; (b) (COCl)2, DMSO, TEA, -6O0C;
(c) ethyl azidoacetate, NaOEt, EtOH; (d) PPh3, ether; (e) RCHO, CH3CN, 6O0C; (i) MeOH, CH2SO4, 6O0C.
Example 41 (£)-3-(4-methylphenyl)prop-2-en-l-ol (Compound 41). Following General
Procedure G, ethyl chloroformate (1.2 ml, 12.3 mmol), 4-methylcinnamic acid (2 g, 12.3 mmol) and triethylamine (1.7 ml, 12.3 mmol) in THF (50 ml) were reacted to produce a mixed anhydride, which was then were reacted with NaBH4 ( 1.02 g, 27.2 mmol) in H2O (20 ml) to produce title compound as a white solid.
1H NMR (500 MHz, CDCl3): δ ppm 2.34 (s, 3 H), 4.31 (t, J= 4.88 Hz, 2 H), 6.30 - 6.39 (m, I H), 6.61 (d, ./=16.11 Hz, 1 H), 7.14 (d, J= 8.30 Hz, 2 H), 7.29 (d, J = 8.30 Hz, 2 H).
Example 42
(iϊ)-3-(4-ethylphenyl)acrylaldehyde (Compound 42). General Procedure H. To a solution of oxalyl chloride (5.9 ml, 11.8 mmol, 2 M in CH2Cl2) in CH2Cl2 (20 ml) was added a solution of DMSO (1.1 ml, 15.7 mmol) in CH2Cl2 (3 ml) dropwise at - 60 0C. A solution of (E)-3-(4-ethylphenyl)prop-2-en-l-ol (Compound 40, 1.3 g, 7.8 mmol) in CH2Cl2 (5 ml) was cannulated slowly into the above mixture at -60 0C. After the reaction was stirred at the same temperature for 1 hour, a solution of triethylamine (4.4 ml, 31.4 mmol) in CH2Cl2 (5 ml) was added into the reaction, which was stirred an additional 1 hour at -60 0C. The reaction was quenched with water, and the products were extracted with CH2Cl2. The organic layer was washed with 5% aqueous NaHCO3, and brine, and dried over MgSO4. The filtered solution was concentrated in vacuo, and the residue was purified by column chromatography (silica gel, 15% ethyl acetate in hexane) to obtain the title compound as a clear oil. 1H NMR (500 MHz, CDCl3): δ ppm 1.26 (t, J= 7.32 Hz, 3 H), 2.70 (q, J= 7.32 Hz, 2 H), 6.72 (dd, J=7.81, 16.11 Hz, 1 H), 7.28 (d, J= 8.30 Hz, 2 H), 7.48 (d, J = 15.62 Hz, 1 H),7.50 (d, J= 8.30 Hz, 2 H), 9.70 (s, 1 H).
Example 43
(£)-3-(4-methylphenyl)acrylaldehyde (Compound 43). Following General Procedure H, oxalyl chloride (7.1 ml, 14.2 mmol, 2 M in CH2Cl2), DMSO (1.3 ml, 18.9 mmol), (E)-3-(4-methylphenyl)prop-2-en-l-ol (Compound 41, 1.4 g, 9.5 mmol) and triethylamine (4.4 ml, 31.4 mmol)in CH2Cl2 (5 ml) were reacted to obtain the title compound as an oil. 1H NMR (500 MHz, CDCl3): δ 2.40 (s, 3 H), 6.72 (dd, J=7.81, 16.11 Hz, 1 H), 7.25 (d, J= 7.81 Hz, 2 H), 7.44 (d, J= 16.11 Hz, 1 H),7.48 (d, J= 8.30 Hz, 2 H), 9.70 (s, 1 H).
Example 44 Ethyl (2Z,4iϊ)-2-azido-5-(4-ethylphenyl)penta-2,4-dienoate (Compound 44).
General Procedure I. A solution of NaOEt in ethanol was prepared in situ by dissolving Na (948 mg, 41.3 mmol) in 30 ml of ethanol. To this solution was added a solution of (£)-3-(4-ethylphenyl)acrylaldehyde (Compound 42, 1.Ig , 6.9 mmol) and ethyl azidoacetate (13 ml, 41.3 mmol) in EtOH (20 ml) dropwise at -10 0C. After the addition was complete, the solution was stirred for an additional 1 hour at -10 0C. The reaction was quenched by adding water, and the product was extracted with ethyl acetate. The organic phase was washed with water, and brine, and dried over Mg2SO4. The solvent was removed in vacuo, and the residue was purified by column chromatography (silica gel, 20% ethyl acetate in hexane) to obtain the title compound as a pale solid.
1H NMR (500 MHz, CDCl3): δ 1.24 (t, J= 7.81 Hz, 3 H), 1.37 (t, J= 7.32 Hz, 3 H), 2.66 (q, J= 7.81 Hz, 2 H), 4.34 (q, J= 7.32 Hz, 2 H), 6.76 (d, J=I 1.23 Hz, 1 H), 6.81 (d, J= 16.11 Hz, 1 H), 7.15 (dd, J= 11.23, 15.62 Hz, 1 H), 7.19 (d, J = 8.30 Hz, 2 H),7.39 (d, J= 8.30 Hz, 2 H). Example 45
Ethyl (2Z,4£)-2-azido-5-(4-methylphenyl)penta-2,4-dienoate (Compound 45).
Following General Procedure I, a 1.38 M solution of NaOEt in ethanol (30 ml), (£)-3-(4-methylphenyl)acrylaldehyde (Compound 43, l.lg , 7.5 mmol) and ethyl azidoacetate (12 ml, 37.5 mmol) in EtOH (20 ml) were reacted to produce the title compound as a solid.
1H NMR (500 MHz, CDCl3): δ 1.37 (t, J= 7.32 Hz, 3 H), 2.36 (s, 3 H), 4.34 (q, J = 7.32 Hz, 2 H), 6.76 (d, J=10.25 Hz, 1 H), 6.81 (d, J=15.62 Hz, I H), 7.11 (dd, J = 11.23, 15.62 Hz, 1 H), 7.17 (d, J= 8.30 Hz, 2 H),7.39 (d, J= 7.81 Hz, 2 H). Example 46
3-Ethoxycarbonyl-l,l,l-triphenyl-6-(4-ethylphenyl)-2-aza-lA5-phosphahexa-l, 3,5-triene (Compound 46). General Procedure J. A solution of triphenylphosphine (1.2 g, 4.54 mmol) in diethyl ether (10 ml) was added dropwise to a solution of ethyl (2Z,4ii)-2-azido-5-(4-ethylphenyl)penta-2,4-dienoate
(Compound 44, 1.2 g, 4.54 mmol) in diethyl ether (20 ml) at 0 0C. The solution was stirred for 12 hours at room temperature. Evaporation of solvent afforded a crude yellow solid, which was purified by column chromatography (silica gel, 20 % ethyl acetate in hexane) to give the title compound. 1H NMR (500 MHz, CDCl3): δ 1.04 (t, J = 7.81 Hz, 3 H), 1.23 (t, J = 7.32 Hz, 3 H), 2.62 (q, J= 7.81 Hz, 2 H), 3.89 (q, J= 7.32 Hz, 2 H), 6.60 (d, J=15.62 Hz, 1 H), 6.70 (dd, J= 3.91, 10.74 Hz, 1 H), 7.12 (d, J= 8.30 Hz, 2 H), 7.30 (d, J= 8.30 Hz, 2 H), 7.41 - 7.50 (m, 9 H), 7.66 (dd, J= 11.23, 15.62 Hz, 1 H),7.73 - 7.77 (m, 6 H). Example 47
3-Ethoxycarbonyl-l,l,l-triphenyl-6-(4-methylphenyl)-2-aza-lA5-phosphahexa- 1, 3,5-triene (Compound 47). Following General Procedure J, triphenylphosphine (1.5 g, 5.8 mmol) ethyl (2Z,4ii)-2-azido-5-(4-methylphenyl)penta-2,4-dienoate (Compound 45, 1.5 g, 5.8 mmol) in diethyl ether (50 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (500 MHz, CDCl3): δ 1.04 (t, J= 7.32 Hz, 3 H), 2.33 (s, 3 H), 3.89 (q, J = 7.32 Hz, 2 H), 6.60 (d, ./=16.1 I Hz, 1 H), 6.70 (dd, J= 3.91, 11.23 Hz, 1 H), 7.09 (d, J= 8.30 Hz, 2 H), 7.27 (d, J= 8.30 Hz, 2 H), 7.41 - 7.50 (m, 9 H), 7.66 (dd, J = 11.23, 16.11 Hz, 1 H), 7.73 - 7.77 (m, 6 H). Example 48
Ethyl 5-(4-ethylphenyl)-6-(4-(trifluoromethyl)phenyl)pyridine-2-carboxylate (Compound 48). General Procedure K. 4-(trifluoromethyl)benzaldehyde (153 mg, 1.88 mmol) was added to a stirred solution of 3-ethoxycarbonyl-l,l,l- triphenyl-6-(4-ethylphenyl)-2-aza-l/i5-phosphahexa-l, 3,5-triene (Compound 46, 444 mg, 0.88 mmol) in dry acetonitrile (10 ml) and the solution was heated to 60 0C for 18 hours. The solution was concentrated in vacuo, and the crude product was passed through a silica gel column with 15% ethyl acetate in hexane as eluant to give the title compound as a yellow oil.
1H NMR (500 MHz, CDCl3): δ 1.24 (t, J= 7.81 Hz, 3 H), 1.46 (t, J= 7.32 Hz, 3 H), 2.67 (q, J= 7.81 Hz, 2 H), 4.51 (q, J= 7.32 Hz, 2 H), 7.09 (d, J= 8.30 Hz, 2 H), 7.16 (d, J= 8.30 Hz, 1 H), 7.49 - 7.55 (m, 4 H), 7.88 (d, J= 7.81 Hz, 1 H), 8.16 (d, J= 7.81 Hz, 1 H). Example 49
Ethyl 3-(4-Ethylphenyl)-[2,4']-bipyridinyl-6-carboxylate (Compound 49).
Following General Procedure K, 4-pyridinecarboxaldehyde (92 mg, 0.86 mmol) and 3-ethoxycarbonyl- 1,1,1 -triphenyl-6-(4-ethylphenyl)-2-aza- 1 l5-phosphahexa- 1 , 3,5-triene (Compound 46, 434 mg, 0.86 mmol) in dry acetonitrile (10 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (500 MHz, CDCl3): δ 1.24 (t, J= 7.81 Hz, 3 H), 1.46 (t, J= 7.32 Hz, 3 H), 2.67 (q, J= 7.81 Hz, 2 H), 4.51 (q, J= 7.32 Hz, 2 H), 7.09 (d, J= 8.30 Hz, 2 H), 7.16 (d, J= 8.30 Hz, 1 H), 7.33 (dd, J= 1.46, 4.39 Hz, 2 H), 7.90 (d, J= 7.81 Hz, 1 H), 8.21 (d, J= 7.81 Hz, 1 H), 8.52 (dd, J= 1.46, 4.39 Hz, 2 H). Example 50
Ethyl 3-(4-Ethylphenyl)-[2,2']-bipyridinyl-6-carboxylate (Compound 50).
Following General Procedure K, 2-pyridinecarboxaldehyde (41 mg, 0.38 mmol) and 3-ethoxycarbonyl- 1,1,1 -triphenyl-6-(4-ethylphenyl)-2-aza- 1 l5-phosphahexa- 1 , 3,5-triene (Compound 46, 193 mg, 0.38 mmol) in dry acetonitrile (5 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (500 MHz, CDCl3): δ 1.22 (t, J= 7.81 Hz, 3 H), 1.45 (t, J= 7.32 Hz, 3 H), 2.62 (q, J= 7.81 Hz, 2 H), 4.52 (q, J= 7.32 Hz, 2 H), 7.05 - 7.11 (m, 4 H), 7.17 - 7.20 (m, 1 H), 7.49 (dd, J =0.98, 7.81 Hz, 1 H), 7.58 -7.62 (m, 1 H), 7.92 (d, J= 7.81 Hz, 1 H), 8.20 (d, J= 7.81 Hz, 1 H), 8.50 - 8.55 (m, 1 H).
Example 51
Methyl 5-(4-Ethylphenyl)-6-(4-(trifluoromethyl)phenyl)pyridine-2-carboxylate (Compound 51). Following General Procedure E, ethyl 5-(4-ethylphenyl)-6-(4- (trifluoromethyl)phenyl)pyridine-2-carboxylate (Compound 48, 60 mg, 0.15 mmol) and cone. H2SO4 (10 drops) in methanol were reacted to produce the title compound as a light yellow solid.
1H NMR (500 MHz, CDCl3): δ ppm 1.24 (t, J= 7.81 Hz, 3 H), 2.67 (q, J= 7.81 Hz, 2 H), 4.03 (s, 3 H), 7.09 (d, J= 8.30 Hz, 2 H), 7.16 (d, J= 8.30 Hz, 1 H), 7.49 - 7.55 (m, 4 H), 7.89 (d, J= 7.81 Hz, 1 H), 8.18 (d, J= 7.81 Hz, 1 H).
Example 52
Methyl 5-(4-Ethylphenyl)-6-(pyridin-4-yl)pyridine-2-carboxylate (Compound
52). Following General Procedure E, ethyl 5-(4-ethylphenyl)-6-(pyridine-4- yl)phenyl)pyridine-2-carboxylate (Compound 49, 48 mg, 0.14 mmol) and cone. H2SO4 (10 drops) in methanol were reacted to produce the title compound as a light yellow solid.
1H NMR (500 MHz, CDCl3): δ ppm 1.24 (t, J= 7.81 Hz, 3 H), 2.65 (q, J= 7.81 Hz, 2 H), 4.03 (s, 3 H), 7.09 (d, J= 7.81 Hz, 2 H), 7.16 (d, J= 7.81 Hz, 1 H), 7.32 (dd, J= 1.46, 4.39 Hz, 2 H), 7.90 (d, J= 8.30 Hz, 1 H), 8.21 (d, J= 8.30 Hz, 1 H), 8.52 (dd, J= 1.46, 4.39 Hz, 2 H).
Example 53
Methyl 5-(4-ethylphenyl)-6-(pyridin-2-yl)pyridine-2-carboxylate (Compound
53). Following General Procedure E, ethyl 5-(4-ethylphenyl)-6-(pyridine-2- yl)phenyl)pyridine-2-carboxylate (Compound 50, 16 mg, 0.05 mmol) and cone.
H2SO4 (10 drops) in methanol were reacted to produce the title compound as a light yellow solid. 1H NMR (500 MHz, CDCl3): δ ppm 1.22 (t, J= 7.81 Hz, 3 H), 2.63 (q, J= 7.81 Hz, 2 H), 4.02 (s, 3 H), 7.05 - 7.11 (m, 4 H), 7.18 - 7.22 (m, 1 H), 7.42 (dd, J =0.98, 7.81 Hz 1 H), 7.56 - 7.63 (m, 1 H), 7.93 (d, J= 8.30 Hz, 1 H), 8.23 (d, J = 8.30 Hz, 1 H), 8.55 -8.57 (m, 1 H). Example 54
5, 6-diphenylpyridine-2-carbaldehyde (Compound 54). General Procedure L.
To a solution of ethyl 5,6-diphenylpyridine-2-carboxylate (Compound 21, 145 mg, 0.48 mmol) in CH2Cl2 (5 ml) at -78 0C was added DIBAL-H (0.72 ml, 0.72 mmol, 1.0 M in Toluene) and the mixture was stirred between -78 0C and -600C for 1 hour under argon. The reaction was quenched with aq, NH4Cl, diethyl ether and
400 mg Celite were added, and the mixture was stirred at room temperature 30 min. The solid was filtered off and rinsed with ether, and the combined filtrate was concentrated in vacuo, and the residue was purified by column chromatography (silica gel, 15% ethyl acetate in hexane) to produce the title compound. 1H NMR (500 MHz, CDCl3) δ 7.17 - 7.22 (m, 2 H), 7.27 - 7.32 (m, 6 H), 7.40 - 7.43 (m, 2 H), 7.92 (d, J= 7.91 Hz, 1 H), 8.01 (d, J= 7.91 Hz, 1 H), 10.19 (s, 1 H).
Scheme 4
21 R1 = H, R2 = phenyl 54 R1 = H, R2 = phenyl 60 R1 = Me
22 R1 = Me, R2 = phenyl 55 R1 = Me, R2 = phenyl 61R1 = = Et
23 R1 = Et, R2 = phenyl 56 R1 = Et, R2 = phenyl 62 R1 = κ-Pr
25 R1 KT3, R2 = phenyl 57 R1 =CF3, R2 = phenyl
49 R1 = Et, R2 = 4-pyπdyl 58 R1 = Et, R2 = 4-pyπdyl
24 R1 = K-Pr, R2 = phenyl 59 R1 = κ-Pr, R2 = phenyl
63 R1 = H, R2 = phenyl, n = 3 72 R1 = Et
64 R1 = Me, R2 = phenyl, n = 3 73 R1 = Me
65 R1 = Et, R2 = phenyl, n = 3 74 R1 = κ-Pr
66 R1 = Et, R2 = phenyl, n = 2
67 R1 =CF3, R2 = phenyl, n = 3
68 R1 = Et, R2 = 4-pyπdyl, n = 3
69 R1 = Et, R2 = 4-pyπdyl, n = 2
70 R1 =Et, R2 = phenyl, n = 4
71 R1 = κ-Pr, R2 = phenyl, n = 3
(a) DiBAL-H, CH2Cl2, -78 0C to -60 0C; (b) n-Bu4NOH, NH2(CH2) nPO3H2, MeOH, Na(BH3)CN, 50 0C; (c)i) NaH, Br(CH2)3PO(OEt)2, DMF, 110 0C; u) TMSI, CHCl3.
Example 55 and Example 60 ό-Phenyl-S-p-tolylpyridine-l-carbaldehyde (Compound 55) and (6-phenyl-5-p- tolylpyridin-2-yl)methanol (Compound 60). Following General Procedure L, ethyl β-phenyl-S-p-tolylpyridine^-carboxylate (Compound 22, 1.1 g, 3.47 mmol) and DIBAL-H (5.2 ml, 5.21 mmol, 1.0M in cyclohexane) in CH2Cl2 (30 ml) were reacted to produce Compound 55 and Compound 60 after separation by column chromatography (silica gel, 15% ethyl acetate in hexane).
Compound 55: 1U NMR (500 MHz, CDCl3): δ 2.38 (s, 3 H), 7.08 - 7.18 (m, 4 H), 7.29 - 7.38 (m, 3 H, 7.42 - 7.52 (m, 2 H), 7.94 (d, J= 7.32 Hz, 1 H), 8.03 (d, J = 7.81 Hz, I H), 10.27 (s, I H). Compound 60: 1H NMR (300 MHz, CDCl3): δ 2.34 (s, 3 H), 4.84 (s, 2 H), 7.02 - 7.13 (m, 4 H), 7.21 - 7.31 (m, 4 H), 7.35 - 7.42 (m, 2 H), 7.71 (d, J= 7.62 Hz, 1 H).
Example 56 and Example 61
5-(4-Ethylphenyl)-6-phenylpyridine-2-carbaldehyde (Compound 56) and [5-(4- Ethylphenyl)-6-phenylpyridin-2-yl]-methanol (Compound 61). Following General Procedure L, ethyl 5-(4-ethylphenyl)-6-phenylpyridine-2-carboxylate (Compound 23, 200 mg, 0.60 mmol) and DIBAL-H (1.2 ml, 1.20 mmol, 1.0 M in CH2Cl2) in CH2Cl2 (5 ml) were reacted to produce Compound 56 and Compound 61 after separation by column chromatography (silica gel, 15% ethyl acetate in hexane).
Compound 56: 1H NMR (500 MHz, CDCl3): δ 1.27 (t, J= 7.81 Hz, 3 H), 2.67 (q, J= 7.81 Hz, 2 H), 7.13 - 7.17 (m, 4H), 7.30 - 7.34 (m, 3 H), 7.44 - 7.47 (m, 2 H), 7.93 (d, J= 7.81 Hz, 1 H), 8.02 (d, J= 7.81 Hz, 1 H), 10.23 (s, 1 H).
Compound 61: 1H NMR (300 MHz, CDCl3): δ ppm 1.24 (t, J= 7.81 Hz, 3 H), 2.66 (q, J= 7.81 Hz, 2 H), 4.85 (d, J= 3.42 Hz, 2 H), 7.08 - 7.13 (m, 4H), 7.25 - 7.28 (m, 5 H), 7.39 (d, J= 7.81 Hz, 1 H), 7.74 (d, J= 7.81 Hz, 1 H).
Example 57
5-(4-Trifluoromethylphenyl)-6-phenylpyridine-2-carbaldehyde (Compound
57). Following General Procedure L, ethyl 5-(4-trifluoromethylphenyl)-6- phenylpyridine-2-carboxylate (Compound 25, 74 mg, 0.20 mmol) and DIBAL-H (0.3 ml, 0.30 mmol, 1.0 M in hexane) in CH2Cl2 (3 ml) were reacted to produce the title compound after purification by column chromatography (silica gel, 15% ethyl acetate in hexane).
1H NMR (300 MHz, CDCl3) δ 7.29 - 7.39 (m, 2 H), 7.45 - 7.62 (m, 4 H), 7.95 (d, J = 7.92 Hz, 1 H), 8.05 (d, J= 7.92 Hz, I H), 10.19 (s, 1 H). Example 58
3-(4-Ethylphenyl)-[2,4l]-bipyridinyl-6-carbaldehyde (Compound 58)
Following General Procedure L, ethyl 3-(4-ethylphenyl)-[2,4']-bipyridinyl-6- carboxylate (Compound 49, 164 mg, 0.49 mmol) and DIBAL-H (0.75 ml, 0.75 mmol, 1.0 M in CH2Cl2) in CH2Cl2 (5 ml) were reacted to produce the title compound after purification by column chromatography (silica gel, 15% ethyl acetate in hexane).
1H NMR (300 MHz, CDCl3): δ 1.25 (t, J= 7.81 Hz, 3 H), 2.68 (q, J= 7.81 Hz, 2 H), 7.11 ((d, J= 8.30 Hz, 2 H), 7.18 (d, J= 7.81 Hz, 1 H), 7.34 (dd, J= 1.95, 4.39 Hz, 2 H), 7.94 (d, J= 7.32 Hz, 1 H), 8.06 (d, J= 7.81 Hz, 1 H), 8.56 (dd, J= 1.95, 4.39 Hz, 2 H), 10.17 (s, I H).
Example 59 and Example 62
6-Phenyl-5-(4-propylphenyl)pyridine-2-carbaldehyde (Compound 59) and (6- Phenyl-5-(4-propylphenyl)pyridin-2-yl)methanol (Compound 62). Following General Procedure L, ethyl 6-phenyl-5-(4-propyl-phenyl)-pyridine-2-carboxylate (Compound 24, 370 mg, 0.49 mmol) and DIBAL-H (2.1 ml, 2.1 mmol, 1.0 M in cyclohexane) in CH2Cl2 (5 ml) were reacted to produce Compound 59 and Compound 62 after separation by column chromatography (silica gel, 15% ethyl acetate in hexane). Compound 59: 1H NMR (500 MHz, CDCl3): δ 0.94 (t, J= 7.32 Hz, 3 H) ,1.59 -
1.71 (m, 2 H), 2.54 - 2.62 (m, 2 H), 7.11 (s, 4 H), 7.26 - 7.35 (m, 3 H), 7.40 - 7.45 (m, 2 H), 7.91 (d, J= 7.81 Hz, 1 H), 7.99 (d, J= 7.81 Hz, I H), 10.19 (s, 1 H).
Compound 62: 1H NMR (500 MHz, CDCl3): δ 0.94 (t, J= 7.32 Hz, 3 H), 1.60 - 1.70 (m, 2 H), 2.54 - 2.62 (m, 2 H), 4.87 (s, 2 H), 7.04 - 7.13 (m, 4 H), 7.22 - 7.32 (m, 4 H), 7.40 (d, J= 7.32 Hz, 2 H), 7.77 (d, J= 7.81 Hz, 1 H).
Example 63
{3-[(5,6-Diphenylpyridin-2-ylmethyl)-amino]-propyl}-phosphonic Acid (Compound 63). General Procedure M. To a solution of 5,6-diphenylpyridine-2- carbaldehyde (Compound 54, 95 mg, 0.37 mmol) and (3-amino-propyl)- phosphonic acid (51 mg, 0.37 mmol) in MeOH (3 ml) was added Bu4NOH (0.4 ml, 0.37 mmol, IM in MeOH) under argon. The mixture was stirred at 50 0C for 30 min. before adding NaCNBH3 (23 mg, 0.37 mmol) to the mixture. The solution was stirred at 50 0C for 3 hours, and then it was concentrated in vacuo. The resulting crude solid was purified MPLC column chromatography (silica gel, 0 - 100% MeOH in ethyl acetate) to obtain the title compound as a white solid.
1H NMR (300 MHz, CDCl3): δ 1.69 - 1.76 (m, 2 H), 2.00 - 2.08 (m, 2 H), 3.09 (t, J= 6.95 Hz, 2 H), 4.19 (s, 2 H), 7.02 - 7.09 (m, 2 H), 7.19 - 7.26 (m, 5 H), 7.30 - 7.36 (m, 3 H), 7.60 - 7.72 (m, 2 H).
Example 64
{3-[(6-Phenyl-5-p-tolylpyridin-2-ylmethyl)-amino]-propyl}-phosphonic Acid (Compound 64). Following General Procedure M, 6-phenyl-5-/?-tolylpyridine-2- carbaldehyde (Compound 55, 67 mg, 0.25 mmol), (3-aminopropyl)-phosphonic acid (34 mg, 0.25 mmol), Bu4NOH (0.2 ml, 0.25 mmol, 1 M in MeOH) and
NaCNBH3 (15 mg, 0.25 mmol) in MeOH (3 ml) were reacted to produce the title compound as a white solid.
1H NMR (500 MHz, CD3OD): δ 1.69 - 1.76 (m, 2 H), 2.00 - 2.08 (m, 2 H), 2.34 (s, 3 H), 3.19 (t, J= 6.80 Hz, 2 H), 4.39 (s, 2 H), 7.08 - 7.16 (m, 4 H), 7.25 - 7.31 (m, 3 H), 7.39 - 7.42 (m, 2 H), 7.54 (d, J= 7.80 Hz, 1 H), 7.89 (d, J= 7.81 Hz, 1 H).
Example 65
3- { [5-(4-Ethylphenyl)-6-phenylpyridin-2-ylm ethyl] -amino}-propyl)- phosphonic Acid (Compound 65). Following General Procedure M, 5-(4- ethylphenyl)-6-phenylpyridine-2-carbaldehyde (Compound 56, 43 mg, 0.15 mmol), (3-aminopropyl)-phosphonic acid (21 mg, 0.15 mmol), Bu4NOH (0.15 ml, 0.15 mmol, 1 M in MeOH) and NaCNBH3 (9 mg, 0.15 mmol) in MeOH (3 ml) were reacted to produce the title compound as a white solid. 1H NMR (500 MHz, CD3OD): δ 1.24 (t, J= 7.81 Hz, 3 H), 1.69 - 1.75 (m, 2 H), 2.00 - 2.08 (m, 2 H), 2.66 (q, J= 7.81 Hz, 2 H), 3.19 (t, J= 6.35 Hz, 2 H), 4.36 (s, 2 H), 7.10 - 7.16 (m, 4 H), 7.25 - 7.31 (m, 3 H), 7.39 - 7.42 (m, 2 H), 7.54 (d, J = 8.30 Hz, 1 H), 7.88 (d, J= 7.81 Hz, 1 H). Example 66
(2-{[5-(4-Ethyl-phenyl)-6-phenyl-pyridin-2-ylmethyl]-amino}-ethyl)- phosphonic Acid (Compound 66). Following General Procedure M, 5-(4-ethyl- phenyl)-6-phenyl-pyridine-2-carbaldehyde (Compound 56, 31 mg, 0.11 mmol), (3- amino-ethyl)-phosphonic acid (14 mg, 0.11 mmol), Bu4NOH (0.11 ml, 0.11 mmol, 1 M in MeOH) and NaCNBH3 (7 mg, 0.11 mmol) in MeOH (2 ml) were reacted to produce the title compound as a white solid.
1H NMR (500 MHz, CD3OD): δ 1.23 (t, J= 7.81 Hz, 3 H), 1.90 - 1.96 (m, 2 H), 2.66 (q, J= 7.81 Hz, 2 H), 3.19 (t, J= 6.35 Hz, 2 H), 4.34 (s, 2 H), 7.09 - 7.16 (m, 4 H), 7.25 - 7.29 (m, 3 H), 7.39 - 7.42 (m, 2 H), 7.53 (d, J= 7.81 Hz, 1 H), 7.87 (d, J= 8.30 Hz, I H).
Example 67
(3-{[6-Phenyl-5-(4-trifluoromethylphenyl)-pyridin-2-ylmethyl]-amino}- propyl)-phosphonic Acid (Compound 67). Following General Procedure M, 5-(4- trifluoromethylphenyl)-6-phenyl-pyridine-2-carbaldehyde (Compound 57, 58 mg, 0.18 mmol), (3-amino-propyl)-phosphonic acid (25 mg, 0.18 mmol), Bu4NOH
(0.18 ml, 0.18 mmol, 1 M in MeOH) and NaCNBH3 (11 mg, 0.18 mmol) in MeOH (3 ml) were reacted to produce the title compound as a white solid.
1H NMR (500 MHz, CD3OD): δ 1.02 (t, J= 7.33 Hz, 3 H), 1.65 - 1.75 (m, 2 H), 1.95 - 2.08 (m, 2 H), 3.16 (t, J= 6.35 Hz, 2 H), 4.36 (s, 2 H), 7.16 - 7.21 (m, 2 H), 7.29 - 7.31 (m, 3 H), 7.52 - 7.59 (m, 5 H), 7.91 (d, J= 7.92 Hz, 1 H).
Example 68
(3-{ [3-(4-Ethylphenyl)- [2,4'] -bipyridin-6-ylmethyl] -amino}-propyl)- phosphonic Acid (Compound 68). Following General Procedure M, 3-(4-ethyl- phenyl)-[2,4']-bipyridinyl-6-carbaldehyde (Compound 58, 50 mg, 0.17 mmol), (3- amino-propyl)-phosphonic acid (24 mg, 0.17 mmol), Bu4NOH (0.17 ml, 0.17 mmol, 1 M in MeOH) and NaCNBH3 (11 mg, 0.17 mmol) in MeOH (3 ml) were reacted to produce the title compound as a white solid. 1H NMR (500 MHz, CD3OD): δl.25 (t, J= 7.81 Hz, 3 H), 1.69 -1.79 (m, 2 H), 2.00 - 2.09 (m, 2 H), 2.66 (q, J= 7.81 Hz, 2 H), 3.17 (t, J= 6.83 Hz, 2 H), 4.37 (s, 2 H), 7.16 (d, J= 8.30 Hz, 2 H), 7.22 (d, J= 8.30 Hz, 2 H), 7.49 (dd, J= 1.95, 4.88 Hz, 2 H), 7.64 (d, J= 7.81 Hz, 1 H), 7.94 (d, J= 7.81 Hz, 1 H), 8.45 (dd, J= 1.46, 4.39 Hz, 2 H). Example 69
(2-{ [3-(4-Ethyl-phenyl)- [2,4'] -bipyridinyl-6-ylmethyl] -amino}-ethyl)- phosphonic Acid (Compound 69). Following General Procedure M, 3-(4-ethyl- phenyl)-[2,4']-bipyridinyl-6-carbaldehyde (Compound 58, 39 mg, 0.14 mmol), (3- amino-ethyl)-phosphonic acid (17 mg, 0.14 mmol), Bu4NOH (0.14 ml, 0.14 mmol, 1 M in MeOH) and NaCNBH3 (9 mg, 0.14 mmol) in MeOH (3 ml) were reacted to produce the title compound as a white solid.
1H NMR (500 MHz, CD3OD): δ 1.25 (t, J= 7.81 Hz, 3 H), 1.90 -1.99 (m, 2 H), 2.69 (q, J= 7.81 Hz, 2 H), 3.30 (t, J= 6.83 Hz, 2 H), 4.39 (s, 2 H), 7.14 (d, J= 8.30 Hz, 2 H), 7.20 (d, J= 8.30 Hz, 2 H), 7.48 (dd, J= 1.46, 4.39 Hz, 2 H), 7.62 (d, J = 7.81 Hz, 1 H), 7.93 (d, J= 7.81 Hz, 1 H), 8.45 (dd, J= 1.95, 4.88 Hz, 2 H).
Example 70
4-((5-(4-Ethylphenyl)-6-phenylpyridin-2-yl)methylamino)butylphosphonic Acid (Compound 70). Following General Procedure M, 5-(4-ethyl-phenyl)-6- phenyl-pyridine-2-carbaldehyde (Compound 56, 58 mg, 0.18 mmol), 4- aminobutylphosphonic acid (21 mg, 0.18 mmol), Bu4NOH (0.18 ml, 0.18 mmol, 1 M in MeOH) and NaCNBH3 (9 mg, 0.18 mmol) in MeOH (2 ml) were reacted to produce the title compound as a white solid. 1H NMR (500 MHz, CD3OD): δ 1.23 (t, J= 7.81 Hz, 3 H), 1.56 - 1.70 (m, 6 H), 2.61 - 2.71 (m. 4 H), 3.85 (s, 2 H), 7.07 - 7.12 (m, 4 H), 7.25 - 7.33 (m, 5 H), 7.66 (d, J= 8.30 Hz, 1 H), 7.83 (d, J= 8.30 Hz, 1 H).
Example 71 3-((6-Phenyl-5-(4-propylphenyl)pyridin-2-yl)methylamino)propylphosphonic
Acid (Compound 71). Following General Procedure M, 6-phenyl-5-(4- propylphenyl)pyridine-2-carbaldehyde (Compound 59, 74 mg, 0.25 mmol), (3- amino-propyl) phosphonic acid (34 mg, 0.25 mmol), Bu4NOH (0.25 ml, 0.25 mmol, IM in MeOH) and NaCNBH3 (15 mg, 0.25 mmol) in MeOH (5 ml) were reacted to produce the title compound as a white solid.
1H NMR (500 MHz, CD3OD) δ 0.94 (t, J= 7.32 Hz, 3 H), 1.58 - 1.78 (m, 4 H), 1.92 - 2.09 (m, 2 H), 2.51 - 2.66 (m, 2 H), 3.05 (t, J= 6.59 Hz, 2 H), 4.23 (s, 2 H), 7.03 - 7.16 (m, 4 H), 7.19 - 7.32 (m, 3 H), 7.36 - 7.38 (m, 2 H), 7.55 (d, J= 7.81 Hz, 1 H), 7.85 (d, J= 8.30 Hz, 1 H). Example 72
{3-[5-(4-Ethyl-phenyl)-6-phenyl-pyridin-2-ylmethoxy]-propyl}-phosphonic Acid (Compound 72). General Procedure N. To a suspension of NaH (11 mg,
0.48 mmol) in DMF (1 ml) was added a solution of [5-(4-ethyl-phenyl)-6-phenyl- pyridin-2-yl] -methanol (Compound 61, 69 mg, 0.24 mmol) at 0 0C under argon. After the mixture was stirred for 30 min., a solution of (3-bromo-propyl)- phosphonic acid diethyl ester (123 mg, 0.48 mmol) was added into the mixture and the reaction was heated to 110 0C overnight. The reaction was quenched with water, and the products were extracted with ethyl acetate. The combined organic layers were washed with water, and brine, and dried over Na2SO4. The filtered solvents were concentrated in vacuo, and the residue was purified by MPLC on silica gel (0 - 100 % ethyl acetate in hexane) to produce a crude mixture containing {3-[5-(4-Ethyl-phenyl)-6-phenyl-pyridin-2-ylmethoxy]-propyl}-phosphonic acid diethyl ester. To a solution of crude {3-[5-(4-ethyl-phenyl)-6-phenyl-pyridin-2-ylmethoxy]- propyl}-phosphonic acid diethyl ester (18 mg, 0.039 mmol) in CHCI3 (2 ml) at room temperature was added TMSI (77 mg, 0.39 mmol) dropwise. After the mixture was stirred for 1 hour, the solvent was removed in vacuo to recover a yellow oily residue. The residue was taken-up in THF/H2O (4:1) and stirred at room temperature overnight. The mixture was extracted with ethyl acetate. The combined organic layers were washed with NaHSO3, and water, and brine, and dried over Na2SO4. The filtered solvents were concentrated in vacuo and the residue was purified by MPLC on silica gel (0 - 100% MeOH in ethyl acetate) to give the title compound as a white solid..
1H NMR (500 MHz, CD3OD): δl.20 (t, J= 7.81 Hz, 3 H), 1.67 - 1.73 (m, 2 H), 1.90 - 2.01 (m, 2 H), 2.61 (q, J= 7.81 Hz, 2 H), 3.67 (t, J= 6.35 Hz, 2 H), 4.69 (s,
2 H), 7.04 - 7.10 (m, 4 H), 7.23 - 7.29 (m, 5 H), 7.59 (d, J= 7.81 Hz, 1 H), 7.84 (d, J= 7.81 Hz, I H). Example 73
3-((6-Phenyl-5-p-tolylpyridin-2-yl)methoxy)propylphosphonic Acid (Compound 73). Following General Procedure N, NaH (17 mg, 0.67 mmol), [5- (4-methyl-phenyl)-6-phenyl-pyridin-2-yl]-methanol (Compound 60, 91 mg, 0.33 mmol) in DMF (3 ml) was refluxed to produce crude {3-[5-(4-methyl-phenyl)-6- phenyl-pyridin-2-ylmethoxy]-propyl}-phosphonic acid diethyl ester, which was then reacted with TMSI (0.13 ml, 0.09 mmol) in CHCl3 (3 ml) to obtain the title compound as an oil.
1H NMR (500 MHz, CD3OD) δ 1.73 - 1.88 (m, 2 H), 1.90 - 2.05 (m, 2 H), 2.30 (s,
3 H), 3.69 (t, J= 6.35 Hz, 2 H), 4.69 (s, 2 H), 6.97 - 7.12 (m, 4 H), 7.20 - 7.34 (m, 5 H), 7.58 (d, J= 8.30 Hz, 1 H), 7.86 (d, J= 8.30 Hz, 1 H).
Example 74
3-((6-Phenyl-5-(4-propylphenyl)pyridin-2-yl)methoxy)propylphosphonic Acid (Compound 74). Following General Procedure N, NaH (17 mg, 0.67 mmol), [5- (4-methyl-phenyl)-6-phenyl-pyridin-2-yl]-methanol (Compound 62, 105mg, 0.35 mmol) in DMF (3 ml) was refluxed to produce crude {3-[5-(4-n-propyl-phenyl)-6- phenyl-pyridin-2-ylmethoxy]-propyl}-phosphonic acid diethyl ester, which was then reacted with TMSI (0.13 ml, 0.09 mmol) in CHCl3 (3 ml) to obtain the title compound as an oil.
Example 75 l-(5,6-Diphenyl-pyridin-2-yl)-ethanone (Compound 75). General Procedure O.
To a solution of ethyl 5,6-diphenylpyridine-2-carboxylate (Compound 21, 246 mg, 0.81 mmol) in toluene (5 ml) was added N, N'-dimethylethylenediamine (DMEDA, 78.7 mg, 0.89 mmol) and trimethylaluminum (1.2 ml, 2.44 mmol, 2 M in toluene) dropwise under argon at room temperature. After the mixture was refluxed at 112 0C for 2.5 hours, it was quenched with water, and the products were extracted with ethyl acetate. The combined organic layers were washed with brine, and dried over Na2SO4. The filtered solvents were concentrated in vacuo, and the residue was purified by silica gel chromatography (15 % ethyl acetate in hexane) to give title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 2.81 (s, 3 H), 7.17 - 7.23 (m, 2 H), 7.27 - 7.33 (m, 6 H), 7.40 - 7.46 (m, 2 H), 7.85 (d, J= 7.92 Hz, 1 H), 8.06 (d, J= 8.21 Hz, 1 H).
Scheme 5
> 1 - R2 = H 1 - = τ
21 R1 = 75 R R>2z = H, Rj = Me
25 R1 = CF3, R2 = H 76 R1 = Rz = H, Rj = Et
29 R1 = H, R2 = CF3 77 R1 = CF3, Rz = H, Rj = Me
78 R1 = CF3, Rz = H, Rj = Et
79 R1 = H, R2 = CF3, R3 = Et
80 R1 = R2 =R4 = H, R3 = Me
81 R1 = R2 =R4 = H, R3 = Et
82 R > 11 - = τ R>2z - = H, R 3j - = 1 Me, R4 = Me
83 R1 = R2 = H, R3 = Et, R4 = Me
84 R1 = CF3, R2 = H, R3 = R4 =Me
85 R1 = CF3, R2 = H, R3 = Et, R4 = Me
(a) R3Al, DMEDA, ToI, 1100C; (b) i) NH2OR4, EtOH, Pyridine, 700C
Example 76 l-(5,6-Diphenyl-pyridin-2-yl)-propan-l-one (Compound 76). Following General Procedure O, ethyl 5,6-diphenylpyridine-2-carboxylate (Compound 21, 267 mg, 0.81 mmol) in toluene (5 ml), N, N'-dimethylethylenediamine (DMEDA, 85 mg, 0.97 mmol) and triethylaluminum (2.6 ml, 2.64 mmol, 1 M in hexane) were reacted to give the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 1.25 (t, J= 7.33 Hz, 3 H), 3.35 (q, J= 7.13 Hz, 2 H), 7.16 - 7.24 (m, 2 H), 7.28 - 7.32 (m, 6 H), 7.38 - 7.46 (m, 2 H), 7.85 (d, J = 7.92 Hz, 1 H), 8.05 (d, J= 7.92 Hz, 1 H).
Example 77 1- [6-Phenyl-5-(4-trifluoromethyl-phenyl)-pyridin-2-yl] -ethanone (Compound
77). Following General Procedure O, 6-phenyl-5-(4-trifluoromethyl-phenyl)- pyridine-2-carboxylic acid ethyl ester (Compound 25, 49 mg, 0.13 mmol) in toluene (3 ml), N, N'-dimethylethylenediamine (DMEDA, 13 mg, 0.15 mmol) and trimethylaluminum (0.2 ml, 2.64 mmol, 2 M in toluene) were reacted to produce the title compound as a yellow oil.
1H NMR (300 MHz, CDCl3) δ 2.80 (s, 3 H), 7.12 - 7.23 (m, 2 H), 7.28 - 7.38 (m, 3 H), 7.47 - 7.62 (m, 4 H), 7.89 (d, J= 7.92 Hz, 1 H), 8.11 (d, J= 7.92 Hz, I H).
Example 78 l-[6-Phenyl-5-(4-trifluoromethyl-phenyl)-pyridin-2-yl]-propan-l-one
(Compound 78). Following General Procedure O, 6-phenyl-5-(4-trifluoromethyl- phenyl)-pyridine-2-carboxylic acid ethyl ester (Compound 25, 94 mg, 0.25 mmol) in toluene (3 ml), N, N'-dimethylethylenediamine (DMEDA, 25 mg, 0.28 mmol) and triethylaluminum (0.7 ml, 0.76 mmol, 1 M in hexane) were reacted to produce the title compound as a oil.
1H NMR (300 MHz, CDCl3) δ 1.25 (t, J= 7.18 Hz, 3 H), 3.33 (q, J= 7.33 Hz, 2 H), 7.15 - 7.24 (m, 2 H), 7.28 - 7.40 (m, 3 H), 7.45 - 7.62 (m, 4 H), 7.88 (d, J = 7.92 Hz, 1 H), 8.10 (dd, J= 8.06, 1.91 Hz, 1 H).
Example 79 l-[5-Phenyl-6-(4-trifluoromethyl-phenyl)-pyridin-2-yl]-propan-l-one
(Compound 79). Following General Procedure O, 5-phenyl-6-(4-trifluoromethyl- phenyl)-pyridine-2-carboxylic acid ethyl ester (Compound 29, 292 mg, 0.71 mmol) in toluene (5 ml), N,N'-dimethylethylenediamine (DMEDA, 76 mg, 0.86 mmol) and triethylaluminum (2.4 ml, 0.35 mmol, 1 M in hexane) were reacted to produce the title compound as a oil.
1H NMR (300 MHz, CDCl3) δ 1.25 (t, J= 7.18 Hz, 3 H), 3.35 (q, J= 7.33 Hz, 2 H), 7.27 - 7.43 (m, 7 H), 7.56 (d, J= 8.21 Hz, 2 H), 7.84 (d, J= 7.92 Hz, 1 H), 8.08 (d, J= 7.92 Hz, 1 H). Example 80 l-(5,6-Diphenyl-pyridin-2-yl)-ethanone Oxime (Compound 80). General Procedure P. l-(5,6-Diphenyl-pyridin-2-yl)-ethanone (Compound 75, 119 mg, 0.44 mmol), NH2OH-HCl (103 mg, 1.48 mmol) and pyridine (272 mg, 0.27 mmol) was dissolved in EtOH (2 ml), and the mixture was heated to 70 0C under nitrogen for 3 hours. The reaction was quenched with water, and the product was extracted with ethyl acetate. The combined organic layers were washed with brine, and dried over Na2SO4. The filtered solvents were concentrated in vacuo, and the residue was purified by silica gel chromatography (15 % ethyl acetate in hexane) to give title compound as an oil.
1H NMR (300 MHz, CDCl3) δ 2.47 (s, 3 H), 7.12 - 7.36 (m, 8 H), 7.35 - 7.49 (m, 2 H), 7.71 (d, J= 7.92 Hz, 1 H), 7.87 (d, J= 8.21 Hz, 1 H).
Example 81 l-(5,6-Diphenyl-pyridin-2-yl)-propan-l-one Oxime (Compound 81). Following General Procedure P, l-(5,6-diphenyl-pyridin-2-yl)-propan-l-one (Compound 76, 90 mg, 0.31 mmol), NH2OH-HCl (87 mg, 1.25 mmol) and pyridine (272 mg, 0.27 mmol) in EtOH (2 ml) were reacted to give title compound as a white solid.
1H NMR (300 MHz, CDCl3) δ 1.24 (t, J= 7.48 Hz, 3 H), 3.08 (q, J= 7.52 Hz, 2 H), 7.13 - 7.35 (m, 8 H), 7.35 - 7.46 (m, 2 H), 7.70 (d, J= 8.21 Hz, 1 H), 7.84 (d, J = 7.92 Hz, 1 H).
Example 82 l-(5,6-Diphenyl-pyridin-2-yl)-ethanone O-Methyloxime (Compound 82). General Procedure Q. To a suspension of NaH (20 mg, 0.80 mmol) in THF (2 ml) at 0 0C was added a solution of l-(5,6-diphenyl-pyridin-2-yl)-ethanone oxime (Compound 80, 46 mg, 0.16 mmol) in THF (1 ml). After the mixture was stirred at the same temperature for 1 hour, MeI (140 mg, 0.99 mmol) was added and the solution was stirred overnight at room temperature. The reaction was quenched with water, and the products were extracted with ethyl acetate. The combined organic layers were washed with brine and dried over Na2SO4. The filtered solvent was concentrated in vacuo, and the residue was purified by silica gel chromatography (10 % ethyl acetate in hexane) to give title compound as an oil.
1H NMR (300 MHz, CDCl3) δ 2.40 (s, 3 H), 4.06 (s, 3 H), 7.11 - 7.34 (m, 8 H), 7.37 - 7.45 (m, 2 H), 7.69 (d, J= 7.92 Hz, 1 H), 7.94 (d, J= 8.21 Hz, 1 H).
Example 83 l-(5,6-Diphenyl-pyridin-2-yl)-propan-l-one O-Methyloxime (Compound 83).
Following General Procedure Q, l-(5,6-diphenyl-pyridin-2-yl)-propan-l-one oxime (Compound 81, 30 mg, O.lmmol), NaH (4.8 mg, 0.20 mmol) and MeI (140 mg, 0.99 mmol) in THF were reaced to obtain the title compound as an oil.
1H NMR (300 MHz, CDCl3) δ 1.19 (t, J= 7.62 Hz, 3 H), 3.01 (q, J= 7.62 Hz, 2 H), 4.04 (s, 3 H), 7.13 - 7.32 (m, 8 H), 7.37 - 7.45 (m, 2 H), 7.69 (d, J= 7.92 Hz, 1 H), 7.90 (d, J= 8.21 Hz, I H).
Example 84 1- [6-Phenyl-5-(4-trifluoromethyl-phenyl)-pyridin-2-yl] -ethanone O-Methyloxime (Compound 84). Following General Procedure P, l-[6-phenyl-5-(4- trifluoromethyl-phenyl)-pyridin-2-yl]-ethanone (Compound 77, 15 mg, 0.04 mmol), NH2OMe-HCl (15 mg, 0.18 mmol) and pyridine (14 mg, 0.18 mmol) in EtOH (2 ml) were reacted to give title compound as a white solid. (12 mg, 75%). 1H NMR (300 MHz, CDCl3) δ 2.40 (s, 3 H), 4.07 (s, 3 H), 7.12 - 7.24 (m, 2 H), 7.28 - 7.36 (m, 3 H), 7.44 - 7.61 (m, 4 H), 7.73 (d, J= 7.92 Hz, 1 H), 8.00 (d, J = 8.21 Hz, 1 H).
Example 85 l-[6-Phenyl-5-(4-trifluoromethyl-phenyl)-pyridin-2-yl]-propan-l-one O- Methyloxime (Compound 85). Following General Procedure P, l-[6-phenyl-5-(4- trifluoromethyl-phenyl)-pyridin-2-yl]-propan-l-one (Compound 78), (24 mg, 0.07 mmol), NH2OMe-HCl (23 mg, 0.25 mmol) and pyridine (21 mg, 0.28 mmol) in EtOH (2 ml) were reacted to give title compound as a white solid. 1H NMR (300 MHz, CDCl3) δ 1.19 (t, J= 7.48 Hz, 3 H), 2.99 (q, J= 7.62 Hz, 2 H), 4.04 (s, 3 H), 7.12 - 7.22 (m, 2 H),7.27 - 7.37 (m, 3 H), 7.43 - 7.56 (m, 4 H), 7.72 (d, J= 7.92 Hz, 1 H), 7.96 (d, J= 8.21 Hz, 1 H).
Scheme 6
H2 • HI
(a) MeI, EtOH, 60 0C, 30 min; (b) EtOH, rt; (c) mCPBA, CH2Cl2; (d) acetoacetic acid ethyl ester, NaH, THF.
Example 86
3-(Methylthio)-5,6-diphenyl-l,2,4-triazine (86). To a solution of thiosemicarbazide (1 g, 10.97 mmol) in ethanol (10 ml) was added MeI (1.6 g,
10.97 mmol). After the supension was heated at 60 0C for 30 min., the mixture was cooled and concentrated in vacuo to remove solvent. The solid was filtered and washed with ether to produce S-methyl isothiosemicarbazide hydroiodide as a yellow solid (2.5 g, 98%). To the suspension solution of benzyl (1.4 g, 6.46 mmol) in ethanol (20 ml) was added the pre-made S-methyl isothiosemicarbazide hydroiodide (I g, 4.29 mmol) in one portion. After stirring at room temperature overnight, the reaction was quenched by adding NaHCO3 and Na2S2O3 and stirring for 30 min. The mixture was filtered, and the solvent was removed in vacuo, and the residue was purified by column chromatography (15 % ethyl acetate in hexane) to give title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ 2.77 (s, 3 H), 7.28 - 7.47 (m, 6 H), 7.48 - 7.60 (m, 4 H).
Example 87
3-(Methylsulfonyl)-5,6-diphenyl-l,2,4-triazine (87). General Procedure R. To a stirred solution of 3-(methylthio)-5,6-diphenyl-l,2,4-triazine (Compound 86) (858 mg, 3.08 mmol) in anhydrous CH2Cl2 (50 ml) at 0 0C was added a suspension of m-chloroperbenzoic acid (2.1 g, 6.16 mmol) in anhydrous CH2Cl2 (50 ml). After one hour, the reaction was quenched with Na2SO3 (aq.). The organic layer was washed with water, and brine, and dried over Na2SO4. The filtered solvents were concentrated in vacuo, and the residue was purified by column chromatography (20 % ethyl acetate in hexane) to give title compound as a solid. 1H NMR (300 MHz, CDCl3) δ 3.57 (s, 3 H), 7.32 - 7.56 (m, 6 H), 7.58 - 7.70 (m, 4 H) Example 88
Ethyl 2-(5,6-Diphenyl-l,2,4-triazin-3-yl)acetate (88). To a suspension of NaH (41 mg, 1.61 mmol) in THF (2 ml) at 0 0C was added ethyl acetoacetate (105 mg. 0.80 mmol) dropwise. After the mixture was stirred for 15 min, a solution of 3-
(methylsulfonyl)-5,6-diphenyl-l,2,4-triazine (Compound 87) (250 mg, 0.80 mmol) in THF (3 ml) was cannulated into the solution, and the resulting solution was heated to 60 0C for 2 hours. The reaction was then quenched with water. The product was extracted with ethyl acetate. The organic layer was washed with water, and brine, and dried over Na2SO4. The filtered solvent was concentrated in vacuo, and the residue was purified by silica gel chromatography (20 % ethyl acetate in hexane) to give title compound as a solid. 1H NMR (300 MHz, CDCl3) δ 1.31(t, J=7.04 Hz, 3 H), 4.21 - 4.32 (m, 4 H), 7.29 - 7.47 (m, 6 H), 7.52 - 7.59 (m, 4 H).
Example 89
Methyl 6-(4-Ethyl-phenyl)-5-phenyl -l,2,4-triazine-3-carboxylate (89). Following General Procedure E, ethyl 6-(4-ethyl-phenyl)-5 -phenyl -1,2,4-triazine- 3-carboxylic acid (Compound 13, 6 mg, 0.018 mmol) was converted to the title compound.
IH NMR (300 MHz, CDCl3) δ ppm 1.26 (t, J=7.62 Hz, 3 H), 2.69 (q, J=7.72 Hz, 2 H), 4.14 (s, 3 H) 7.22 (d, J=8.50 Hz, 2 H), 7.32 - 7.41 (m, 2 H), 7.43 - 7.51 (m, 1 H), 7.55 (d, J=8.21 Hz, 2 H), 7.62 - 7.70 (m, 2 H).
Example 90
(5,6-diphenylpyridin-2-yl)methanol (90), as AGN-210851. Following General Procedure L, ethyl 5,6-diphenylpyridine-2-carboxylate (Compound 21, 145 mg, 0.48 mmol) was converted to the title compound. 1H NMR (300 MHz, CDCl3) δ ppm 4.76 (s, 2 H), 7.07 - 7.17 (m, 2 H), 7.18 - 7.22 (m, 7H), 7.27 - 7.31 (m, 2 H), 7.64 (d, J= 7.91 Hz, 1 H).
Example 91
5,6-Diphenyl-pyridine-2-carboxylic acid (91). A solution of ethyl 5,6- diphenylpyridine-2-carboxylate (Compound 21, 40 mg, 0.13 mmol) and LiOH (IN, 1 ml) in EtOH (2 ml) was stirred at room temperature overnight. The mixture was acidified with 10% HCl, then extracted with EtOAc. The organic layer was washed with water, and brine, and dried over Na2SO4. The filtered solvent was concentrated in vacuo, and the residue was purified by silica gel chromatography (20 - 80 % Ethyl acetate in hexane) to give title compound as a solid. 1H NMR (300 MHz, CDCl3) δ 7.17 - 7.21 (m, 2 H), 7.26 - 7.37 (m, 8H), 7.97 (d, J = 7.62 Hz, 1 H), 8.23 (d, J= 7.92 Hz, 1 H).
Example 92 6-Methoxymethyl-2,3-diphenyl-pyridine (92). A solution of 5,6-diphenylpyridin- 2-yl)methanol (Compound 90, 15 mg, 0.06 mmol), MeI (0.1 ml), K2CO3 (50 mg) and KOH (5N, 5 drops) in acetone was heated at 56 0C over night. The mixture was diluted with water and the product was extracted with ethyl acetate. . The organic layer was washed with water, and brine, and dried over Na2SO4. The filtered solvent was concentrated in vacuo, and the residue was purified by silica gel chromatography (15 % ethyl acetate in hexane) to give title compound as a solid.
1H NMR (300 MHz, CDCl3) δ 3.54 (s, 3 H), 4.71(s, 2 H), 7.14 - 7.18 (m, 2 H), 7.22- 7.27 (m, 6H), 7.33 - 7.36 (m, 2 H), 7.47 (d, J= 7.92 Hz, 1 H), 7.74 (d, J = 7.92 Hz, 1 H).
Scheme 7
94, R = Me
95, R = Et
(a) i)NaOH, MeOH, 69 0C, 6 hrs, ii) c. H2SO4, MeOH, 69 0C, 3 hrs.; (b) Me3Al, or Et3Al, DMEDA, toluene, HO 0C, 3 hrs.
Example 93
Methyl S^-Diphenyl-pyrazine-l-carboxylate (93). To a solution of benzyl (500 mg, 2.38 mmol) and 2,3 -diaminopropionic acid monohydro chloride (334 mg, 2.38 mmol) in MeOH (10 ml) was added NaOH (380 mg, 9.51 mmol) at room temperature. After the mixture was refluxed for 6 hours, it was cooled down in an ice-bath, cone. H2SO4 (1 ml) was added dropwise and the whole mixture was stirred under reflux for 3 hours. MeOH was removed and the residue was dissolved in water, extracted with ethyl acetate. The organic layer was washed with NaHCO3 (sat.), water, and brine, dried over Na2SO4, concentrated invacuo and purified by column chromatography (15% ethyl acetate in hexane) to give the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ ppm 4.06 (s, 3 H), 7.27 - 7.40 (m, 6 H), 7.45 - 7.54 (m, 4 H), 9.28 (s, 1 H).
Example 94 l-(5,6-Diphenyl-pyrazin-2-yl)-ethanone (94).. Following General Procedure O, methyl 5,6-diphenyl-pyrazine-2-carboxylate (Compound 93, 83 mg, 0.29 mmol), Me3Al (0.4 ml, 2M in toluene), DMEDA (28 mg, 0.32 mmol) in toluene was reacted to afford the title compound.
1H NMR (300 MHz, CDCl3) δ 2.80 (s, 3 H), 7.31 - 7.42 (m, 6 H), 7.47 - 7.56 (m, 4 H), 9.21 (s, 1 H).
Example 95 l-(5,6-Diphenyl-pyrazin-2-yl)-propan-l-one (95). Following General Procedure O, methyl 5,6-diphenyl-pyrazine-2-carboxylate (Compound 93) (92 mg, 0.32 mmol), Et3Al (0.9 ml, IM in hexane), DMEDA (38 mg, 0.35 mmol) in toluene was reacted to afford the title compound.
1H NMR (300 MHz, CDCl3) δ 1.26 (t, J= 7.33 Hz, 3 H), 3.31 (q, J= 7.33 Hz, 2 H), 7.28 - 7.42 (m, 6 H), 7.45 - 7.56 (m, 4 H), 9.20 (s, 1 H).
Scheme 8
105 106
(a) NaOEt, ethyl formate, EtOH, O 0C to rt; (b)/?TSA, methyl urea, toluene, 1 10 0C, 12 hr;
(c) PCl5, POCl3, 120 0C, 3 hrs; (d) CO(g), dppf, Pd(OAc)2, CH3COONa, MeOH, THF, sealed-tube, 1 10 0C.
Example 105
(Z)-3-Hydroxy-2,3-diphenyl-propenal (105). To a cooled soultion of NaOEt (763 mg, 11.21 mmol) in EtOH (100ml) was added ethyl formate (0.91 ml, 11.21 mmol) dropwise. The resulting mixture is allowed to stand for 3 hours at 0 to 5 0C, and then deoxybenzoin (2 g, 10.19 mmol) was added. The mixture was stirred for 2 hours at 0 to 5 0C and then placed in the refrigerator for 4 days. After the mixture was stirred overnight at room temperature, it was poured into ice-water, and acidified, and extracted with CH2Cl2. The organic layer was washed with brine, and dried over MgSO4 anhydride, and concentrated in vacuo. The residue was purified by column chromatography (10% ethyl acetate in hexane) to give the title compound as a light yellow solid.
1H NMR (500 MHz, CDCl3) δ ppm 7.12 - 7.23 (m, 2 H), 7.26 - 7.40 (m, 5 H), 7.41 - 7.50 (m, 3 H), 8.73 (d, J= 5.37 Hz, 1 H).
Example 106 l-Methyl-5,6-diphenyl-lH-pyrimidin-2-one (106). A solution of (Z)-3-hydroxy- 2,3-diphenyl-propenal (105, 423 mg, 1.89 mmol), //TSA (30 mg, 7.56 mmol) and methyl urea (118 mg, 0.62 mmol) in toluene was heated at 110 0C overnight. The reaction was quenched with water, and the products were extracted with ethyl acetate. The organic layer was separated and washed with brine, and dried over MgSO4, and concentrated in vacuo to produce a yellow oil. The crude product was dissolved in CH2Cl2 and titrated with diethyl ether to give the title compound as a white solid. 1H NMR (500 MHz, CDCl3) δ ppm 3.32 (s, 3 H), 6.88 - 7.12 (m, 2 H), 7.07 - 7.25 (m, 3 H), 7.31 - 7.40 (m, 2 H), 7.39 - 7.48 (m, 3 H), 8.58 (s, 1 H).
Example 107
2-Chloro-4,5-diphenyl-pyrimidine (107). A solution of l-methyl-5,6-diphenyl- lH-pyrimidin-2-one (106, 314 mg, 1.20 mmol), phosphorus oxychloride (0.6 ml, 6.4 mmol) and phosphorus pentachloride (55 mg, 0.26 mmol) was heated at 120 0C for 3 hours. The excess amount of phosphorus oxychloride was removed under reduced pressure and cold water was added to the residue. The resulting precipitate was extracted with CH2Cl2. The organic layer was washed with brine, and dried over MgSO4, and concentrated in vacuo. The residue was purified by column chromatography (20% ethyl acetate in hexane) to produce the title compound as a white solid.
1H NMR (500 MHz, CDCl3) δ ppm 7.16 - 7.23 (m, 2 H), 7.24 - 7.32 (m, 3 H), 7.33 - 7.40 (m, 3 H), 7.42 - 7.47 (m, 2 H), 8.59 (s, 1 H).
Example 96 Methyl 4,5-Diphenyl-pyrimidine-2-carboxylate (96). A solution of 2-chloro-4,5- diphenyl-pyrimidine (107, 203 mg, 0.76 mmol) and sodium acetate (188 mg, 2.21 mmol) in MeOH (6 ml) and THF (2 ml) was degassed under argon for 10 min. Pd(OAc)2 (2.1 mg) and DPPF (13 mg) were added and CO (g) was bubbled through the solution. The reaction was heated to 110 0C in a sealed tube for 2 days. The solvent was removed in vacuo and the crude product was purified by column chromatography (10% ethyl acetate in hexane) to get the title compound. 1H NMR (500 MHz, CDCl3) δ ppm 4.14 (s, 3 H), 7.16 - 7.23 (m, 2 H), 7.29 (d, J = 7.32 Hz, 2 H), 7.32 - 7.39 (m, 4 H), 7.49 (d, J= 7.32 Hz, 2 H), 8.54 (s, 1 H).
Scheme 9
(a) mCPBA, CHCl3, 5 days; (b) c.HsSO4, MeOH.
Example 108
Ethyl 5-(4-Ethyl-phenyl)-l-hydroxy-6-phenyl-pyridine-2-carboxylate, N-Oxide
(108). Following General Procedure R, a solution of ethyl 5-(4-ethyl-phenyl)-6- phenyl-pyridine-2-carboxylate (23, 25 mg, 0.076 mmol), m-chloroperbenzoic acid (85 mg, 0.38 mmol) and anhydrous CHCl3 (3 ml) was stirred at room temperature for 7 days to give title compound.
1H NMR (500 MHz, CDCl3) δ ppm 1.21 (t, J= 7.57 Hz, 3 H), 1.45 (t, J= 7.08 Hz, 3 H), 2.61 (q, J= 7.81 Hz, 2 H), 4.51 (q, J= 7.16 Hz, 2 H), 7.01 (d, J= 8.30 Hz, 2 H), 7.05 (d, J= 8.30 Hz, 2 H), 7.29 - 7.31 (m, 4 H), 7.35 (d, J= 7.81 Hz, 1 H), 7.56 (d, J= 7.81 Hz, I H).
Example 97
Methyl 5-(4-Ethyl-phenyl)-l-hydroxy-6-phenyl-pyridine-2-carboxylate, N- Oxide (97).
Following General Procedure E, 5-(4-ethyl-phenyl)-l-hydroxy-6-phenyl-pyridine- 2-carboxylate, N-oxide (108, 6 mg, 0.017 mmol), c. H2SO4 (1 drop) in MeOH was reacted to afford the title compound. 1H NMR (500 MHz, CDCl3) δ ppm 1.18 (t, J= 7.57 Hz, 3 H), 2.58 (q, J= 7.32 Hz, 2 H), 4.00 (s, 3 H), 6.94 - 7.00 (m, 2 H), 7.00 - 7.06 (m, 2 H), 7.27 (s, 4 H), 7.32 (d, J= 9.28 Hz, 1 H), 7.56 (d, J= 8.30 Hz, 1 H).
Scheme 10
98
(a) i) Ethyl chlorofoπnate, TEA, THF, 11) NaBH4, H2O, THF; (b) (COCl)2, DMSO, TEA, -6O0C; (c) ethyl azidoacetate, NaOMe, MeOH; (d) PPh,, ether; (e) PhCHO, CH,CN, 6O0C.
Example 109 (£)-3-(4-Isopropylphenyl)prop-2-en-l-ol (Compound 109). Following General Procedure G, 4-iso-propylcinnamic acid (3 g, 15.8 mmol), ethyl chloro formate (1.6 ml, 15.8 mmol) and triethylamine (2.2 ml, 15.8 mmol) in THF (100ml) were reacted to produce a mixed anhydride, which was then were reacted with NaBH4 (1.3 g, 34.7 mmol) in H2O (30 ml) to produce title compound as a white solid. 1H NMR (300 MHz, CDCl3) δ ppm 1.26 (d, J=7.04 Hz, 6 H), 2.86 - 2.97 (m, 1 H), 4.32 (dd, J=5.86, 1.17 Hz, 2 H), 6.29 - 6.38 (m, IH), 6.61 (d, J=16.12 Hz, 1 H), 7.16 - 7.24 (d, J=8.21 Hz, 2 H), 7.33 (d, J=8.21 Hz, 2 H)
Example 110 (£)-3-(4-Isopropylphenyl)acrylaldehyde (Compound 110). Following General Procedure H, oxalyl chloride (9.5 ml, 19.0 mmol, 2M in CH2Cl2), DMSO (1.8 ml, 25.3 mmol), (£)-3-(4-isopropylphenyl)prop-2-en-l-ol (Compound 109, 2.2g, 12.6 mmol) and triethylamine (7.1 ml, 50.7 mmol) in CH2Cl2 (100 ml) were reacted to obtain the title compound as an oil.
1H NMR (300 MHz, CDCl3) δ ppm 1.28 (d, J=7.04 Hz, 6 H), 2.77 - 3.11 (m, 1 H), 6.70 (dd, J=15.83, 7.62 Hz, 1 H), 7.31 (d, J=8.21 Hz, 1 H), 7.45 - 7.59 (m, 3 H), 9.70 (d, J=7.62 Hz, 1 H)
Example 111 Methyl (2Z,4E)- 2-Azido-5-(4-isopropylphenyl)penta-2,4-dienoate (Compound
111). Following General Procedure I, a 1.34 M solution of NaOMe in methanol (30 ml), (£)-3-(4-isopropylphenyl)acrylaldehyde (Compound 110,1.4 g, 8.0 mmol) and ethyl azidoacetate (12 ml, 40.2 mmol) in MeOH (20 ml) were reacted to produce the title compound as a solid. 1U NMR (300 MHz, CDCl3) δ ppm 1.26 (d, J=6.74 Hz, 6 H), 2.80 - 3.02 (m, 1 H), 3.88 (s, 3 H), 6.70 - 6.87 (m, 2 H), 7.13 (dd, J=15.54, 11.43 Hz, 1 H), 7.22 (d, J=8.21 Hz, 2 H), 7.43 (d, 2 H)
Example 112
3-Methoxycarbonyl-l,l,l-triphenyl-6-(4-isopropylphenyl)-2-aza-lλ5- phosphahexa-l,3,5-triene (Compound 112). Following General Procedure J, triphenylphosphine (1.4g, 5.2 mmol), methyl (2Z,4E)- 2-azido-5-(4- isopropylphenyl)penta-2,4-dienoate (Compound 111, 1.4 g, 5.2 mmol) in diethyl ether (50 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ ppm 1.26 (d, J=6.74 Hz, 6 H), 2.81 - 2.98 (m, 1 H), 3.44 (s, 3 H), 6.58 - 6.76 (m, 2 H), 7.15 (d, J=8.21 Hz, 2 H), 7.32 (d, J=8.50 Hz, 2 H), 7.37 - 7.57 (m, 9 H), 7.76 (ddd, J=12.09, 7.99, 1.32 Hz, 7 H)
Example 98 Methyl 5-(4-Isopropyl-phenyl)-6-phenyl-pyridine-2-carboxylate (Compound
98). Following General Procedure K, Benzaldehyde (0.48 g, 4.6 mmol) and 3- Methoxycarbonyl- 1,1,1 -triphenyl-6-(4-isopropylphenyl)-2-aza- 1 λ5-phosphahexa- 1,3,5-triene (Compound 112, 2.3 g, 4.6 mmol) in dry acetonitrile (100 ml) were reacted to produce the title compound as a yellow solid.
1H NMR (300 MHz, CDCl3) δ ppm 1.25 (d, J=7.04 Hz, 6 H), 2.78 - 3.00 (m, 1 H), 4.03 (s, 3 H), 7.06 - 7.19 (m, 4 H), 7.21 - 7.32 (m, 3 H), 7.35 - 7.46 (m, 2 H), 7.86 (d, J=7.92 Hz, 1 H), 8.14 (d, J=7.92, 1 H)
Scheme 11.
114 115
(a) DMF, 75 0C, 24 hours; (b) NaH, cyanoacetamide, DMF, MeOH, 95 0C 2 hours; (c) POCl3 110 0C; (d) morpholine, DMF, 150 0C, 2 hours; (e) 50% H2SO4, 140 0C, overnight.
Example 113 (E)-3-(Dimethylamino)-l-phenyl-2-p-tolylprop-2-en-l-one (Compound 113). A solution of l-phenyl-2-/?-tolylethanone (2 g, 9.5 mmol) and dimethylformamide dimethylacetal (4.5 g, 38.1 mmol) in DMF (30 ml) was heated at 75 0C for 24 hours. Solvents were removed under high vacuum to obtain the title compound as a yellow oil, which was used directly in the next step without purification.
1H NMR (300 MHz, CDCl3) δ ppm 2.32 (s, 3 H), 2.73 (s, 6 H), 7.06 (s, 4 H), 7.21 - 7.36 (m, 4 H), 7.44 (d, 2 H)
Example 114
2-Hydroxy-6-phenyl-5-p-tolylnicotinonitrile (Compound 114). A solution of (E)-3-(dimethylamino)-l-phenyl-2-/?-tolylprop-2-en-l-one (Compound 113, 500 mg, 1.9 mmol), cyanoacetamide (175 mg, 2.1 mmol) and MeOH (0.2 ml, 2.2 mmol) in DMF (4 ml) was cannulated into a suspension of NaH (119 mg, 4.7 mmol, 95 % in mineral oil) in DMF (2 ml) at room temperature. After the addition was completed, the reaction was heated to 95 0C for 2 hours. The reaction was quenched with water and extracted with ethyl acetate. The organic layer was washed with water and brine, dried over MgSO4, concentrated in vacuo. The solid residue was triturated with diethyl ether, filtered and dried under high vacuum to yield the title compound as a white solid.
1H NMR (300 MHz, CDCl3) δ ppm 2.33 (s, 3 H), 6.94 (d, J=8.21 Hz, 2 H), 7.08 (d, J=7.92 Hz, 2 H), 7.28 - 7.49 (m, 5 H), 7.97 (s, 1 H)
Example 115
2-Chloro-6-phenyl-5-p-tolylnicotinonitrile (Compound 115). A solution of 2- hydroxy-6-phenyl-5-/?-tolylnicotinonitrile (Compound 114, 528 mg, 1.9 mmol) in POCl3 ( 5 ml) was heated to 110 0C overnight. POCl3 was removed and the residue was purified by MPLC column chromatography (silica gel, 10 % ethyl acetate in hexane) to obtain the title compound as an oil-foam.
1H NMR (300 MHz, CDCl3) δ ppm 2.36 (s, 3 H), 6.98 - 7.18 (m, 4 H), 7.21 - 7.45 (m, 5 H), 7.97 (s, 1 H) Example 116 l-Morpholino-ό-phenyl-S-p-tolylnicotinonitrile (Compound 116). A solution of 2-chloro-6-phenyl-5-/?-tolylnicotinonitrile (Compound 115, 124 mg, 0.4 mmol) and morpholine (36 mg, 0.4 mmol) in DMF (2 ml) was heated at 150 0C for 2 hours. The solvents was removed and the residue was purified by MPLC column chromatography (silica gel, 10 % ethyl acetate in hexane) to obtain the title compound as a white solid.
1H NMR (300 MHz, CDCl3) δ ppm 2.34 (s, 3 H), 3.77 - 3.94 (m, 8 H), 6.95 - 7.14 (m, 4 H), 7.18 - 7.34 (m, 3 H), 7.34 - 7.43 (m, 2 H), 7.82 (s, 1 H)
Example 99
4-(6-Phenyl-5-p-tolylpyridin-2-yl)morpholine (Compound 99). A solution of 2- morpholino-6-phenyl-5-/?-tolylnicotinonitrile (Compound 116,120 mg, 0.3 mmol) in 50% H2SO4 (5 ml) was heated at 140 0C overnight. The mixture was cooled down to room temperature and diluted with water, extracted with CH2Cl2. The organic layer was washed with water and brine, dried over MgSO4, concentrated in vacuo and purified by MPLC column chromatography (silica gel, 25% ethyl acetate in hexane) to provide the title compound as a white solid.
1H NMR (300 MHz, CDCl3) δ ppm 2.34 (s, 3 H), 3.63 (d, J=4.98 Hz, 4 H), 3.86 (d, J=4.98 Hz, 4 H), 6.68 (d, J=8.50 Hz, 1 H), 7.05 (s, 4 H), 7.19 - 7.26 (m, 3 H), 7.41 (dd, J=6.89, 3.08 Hz, 2 H), 7.57 (d, J=8.79 Hz, 1 H)
While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced within the scope of the following claims. In particular, the present invention contemplates and includes a compound comprising a 6-membered heteroaromatic ring including one, two or three enchained nitrogen atoms at the 1 , or 1 and 3 or 1 , 3 and 4 positions, respectively, and the remaining ring atoms being carbon, an aryl radical directly bonded to said 6-membered heteroaromatic ring at both of the 5 and 6 positions and a side chain at the 2 position of said 6-membered heteroaromatic ring, wherein said side chain terminates with an end group selected from the group consisting of a phosphonic acid, a lower alkyl ester thereof, a carboxylic acid, a lower alkyl ester thereof, a lower alkyl ether and a lower alkylcarboxy and a compound comprising a 6- membered heteroaromatic ring including one, two or three enchained nitrogen atoms and the remaining ring atoms being carbon, an aryl radical directly bonded to said 6-membered heteroaromatic ring at both of the 5 and 6 positions and a side chain at the 2 position of said 6-membered heteroaromatic ring, wherein said side chain terminates with an end group selected from the group consisting of a phosphonic acid, a lower alkyl ester thereof, a carboxylic acid, a lower alkyl ester thereof, a lower alkyl ether and a lower alkylcarboxy.

Claims

What is claimed is:
Claim 1. A novel compound having agonist activity at the SIP3 receptor which is represented by the formula I
[C(R3)2]a[S(O)f{R3)]b[C(V)x(OR4)y(R4)z]c
I wherein
X is selected from the group consisting of CR , N and NO;
Y is selected from the group consisting of CR3, N and NO; Z is selected from the group consisting of CR3, N and NO; and at least one of X, Y and Z is N or NO;
V is O or NOR4 R1 is an aryl group;
R2 is an aryl group;
R is selected from the group consisting of H and alkyl; and 2 of said R groups may together form a cyclic alkyl ring having from 3 to 6 carbon atoms; R4 is selected from the group consisting of H and alkyl; a is 0 or an integer of from 1 to 6; b is 0 or 1 ; c is 0 or 1 ; f is 0 or an integer of 1 or 2; x is 0 or 1 ; y is 0 or an integer of from 1 to 3; and z is 0 or an integer of from 1 to 3.
Claim 2. The compound of claim 1 wherein R1 is selected, from the group consisting of phenyl and substituted derivatives thereof;
R2 is selected, preferably from the group consisting of phenyl, furanyl, thienyl, pyridyl, pyranyl and substituted derivatives thereof;
R is selected from the group consisting of H and lower alkyl;
R4 is selected from the group consisting of H and lower alkyl; and
a is 0 or an integer of from 1 to 3.
Claim 3. The compound of claim 2, wherein R3 is H.
Claim 4. The compound of claim 3, wherein R1 is represented by the general formula
wherein R5 is selected from the group consisting of H, alkyl, trifluoromethyl, trifluoromethyloxy, halo and lower alkylthio. Claim 5. The compound of claim 4, wherein R is selected from the group consisting of furanyl, thienyl, pyridyl and pyranyl or R2 is
represented by the general formula
wherein R ,
5 is selected from the group consisting of H, alkyl, halo, trifluoromethyl, trifluoromethyloxy and loweralkylthio .
Claim 6. The compound of claim 1 wherein X and Y are CR3 and Z is N.
Claim 7. The compound of claim 1 wherein b is 0, c is 1, x is 1, y is 1 and z is O.
Claim 8. The compound of claim 7 wherein a is 0.
Claim 9. The compound of claim 8, wherein R4 is alkyl.
Claim 10. The compound of claim 1 wherein R1 is a carbocyclic aryl having from 6 to 10 carbon atoms which may be substituted with an alkyl or halo alkyl group.
Claim 11. The compound of claim 10, wherein R1 is phenyl which may be substituted with a lower alkyl or a trifluoromethyl radical.
Claim 12. The compound of claim 1 wherein R is a carbocyclic aryl having from 6 to 10 carbon atoms which may be substituted with an alkyl or haloalkyl group or R2 is pyridyl.
Claim 13. The compound of claim 12 wherein said alkyl group is a lower alkyl radical and said haloalkyl group is trifluoromethyl.
Claim 14. The compound of claim 1 selected from the group consisting of
Ethyl 6-(4-Ethylphenyl)-5-phenyl -1,2,4— triazine-3-carboxylate
Ethyl 6-Phenyl-5-p-tolyl- 1 ,2,4— triazine-3-carboxylate Ethyl 5,6-Diphenylpyridine-2-carboxylate
Ethyl 6-Phenyl-5-/?-tolyl-pyridine-2-carboxylate
Ethyl 5-(4-Ethyl-phenyl)-6-phenyl-pyridine-2-carboxylate
Ethyl 6-Phenyl-5 -(4-propylphenyl)-pyridine-2-carboxylate
Ethyl 5-Phenyl-6-/?-tolyl-pyridine-2-carboxylate Ethyl 5-(4-Ethylphenyl)-6-phenyl-pyridine-2-carboxylate
Methyl 6-(4-Ethyl-phenyl)-5 -phenyl - 1 ,2,4— triazine-3-carboxylate
Methyl 5 ,6-Diphenylpyridine-2-carboxylate
Methyl 6-Phenyl-5 -p-tolyl-pyridine-2-carboxylate
Methyl 5 -(4-Ethylphenyl)-6-phenyl-pyridine-2-carboxylate Methyl 6-Phenyl-5-(4-propylphenyl)-pyridine-2-carboxylate
Methyl 6-Phenyl-5-(4-trifluoromethylphenyl)-pyridine-2-carboxylate
Methyl 5 -(4-Ethylphenyl)-6-(pyridin-4-yl)pyridine-2-carboxylate
1 -(5 ,6-Diphenyl-pyridin-2-yl)-propan- 1 -one
1 - [5 -Phenyl-6-(4-trifluoromethyl-phenyl)-pyridin-2-yl] -propan- 1 -one
6-Methoxymethyl-2,3-diphenyl-pyridine
Methyl 5 ,6-Diphenyl-pyrazine-2-carboxylate
1 -(5 ,6-Diphenyl-pyrazin-2-yl)-ethanone
1 -(5 ,6-Diphenyl-pyrazin-2-yl)-propan- 1 -one .
Claim 15. A compound having agonist activity at the SIP3 receptor comprising a 6-membered heteroaromatic ring including one, two or three enchained nitrogen atoms and the remaining ring atoms being carbon, an aryl radical directly bonded to said 6-membered heteroaromatic ring at both of the 5 and 6 positions and a side chain at the 2 position of said 6-membered heteroaromatic ring, wherein said side chain terminates with an end group selected from the group consisting of a carboxylic acid, a lower alkyl ester thereof, or a pharmaceutically acceptable salt thereof, a lower alkyl ether and a lower alkylcarboxy, or a pharmaceutically acceptable salt thereof.
Claim 16. The compound of claim 15 wherein said one, two or three enchained nitrogen atoms are at the 1, or 1 and 3, or 1 and 4, or 1, 3 and 4 positions, respectively.
EP07841847A 2006-09-07 2007-09-05 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity Withdrawn EP2064183A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82480506P 2006-09-07 2006-09-07
PCT/US2007/077581 WO2008030838A2 (en) 2006-09-07 2007-09-05 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity

Publications (1)

Publication Number Publication Date
EP2064183A2 true EP2064183A2 (en) 2009-06-03

Family

ID=39157985

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07841847A Withdrawn EP2064183A2 (en) 2006-09-07 2007-09-05 Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity

Country Status (6)

Country Link
EP (1) EP2064183A2 (en)
JP (1) JP2010502728A (en)
AU (1) AU2007292436A1 (en)
BR (1) BRPI0716601A2 (en)
CA (1) CA2662850A1 (en)
WO (1) WO2008030838A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741875B2 (en) 2009-11-24 2014-06-03 Allergan, Inc. Compounds as receptor modulators with therapeutic utility
EP2504328A1 (en) 2009-11-24 2012-10-03 Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility
US20110281822A1 (en) 2010-05-14 2011-11-17 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity
US8513220B2 (en) 2010-05-14 2013-08-20 Allergan, Inc. Aromatic compounds having sphingosine-1-phosphonate (S1P) receptor activity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4013654A (en) * 1974-01-31 1977-03-22 Eli Lilly And Company 5,6-diaryl-1,2,4-triazines
US4021553A (en) * 1976-03-10 1977-05-03 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
DE2712694A1 (en) * 1977-03-23 1978-09-28 Degussa METHOD FOR MANUFACTURING SUBSTITUTED PYRIDINS
JP2003531202A (en) * 2000-04-25 2003-10-21 ファルマシア・コーポレーション Regioselective synthesis of 3,4-di (carbocyclyl or heterocyclyl) thiophene
CN1894225A (en) * 2003-12-17 2007-01-10 默克公司 (3,4-disubstituted) propionates as sphingosine 1-phosphate (endothelial differentiation gene) receptor agonists
US20070185116A1 (en) * 2004-05-31 2007-08-09 Tanabe Seiyaku Co., Ltd. Bicyclic compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2008030838A2 *

Also Published As

Publication number Publication date
JP2010502728A (en) 2010-01-28
BRPI0716601A2 (en) 2013-09-17
CA2662850A1 (en) 2008-03-13
WO2008030838A2 (en) 2008-03-13
AU2007292436A1 (en) 2008-03-13
WO2008030838A3 (en) 2008-11-27

Similar Documents

Publication Publication Date Title
US7737173B2 (en) Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
US7728014B2 (en) Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist biological activity
AU2007292347A1 (en) Heteroaromatic compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity
JP2011506445A (en) γ-secretase modulator
KR100742013B1 (en) Process for preparation of 4-aryl-nicotinamide derivatives
TW517056B (en) Substituted vinylpyridine derivatives and the pharmaceutical composition
KR102678781B1 (en) Compounds and pharmaceutical compositions and methods thereof for modulating SGK activity
CA2298480A1 (en) Pyridylacrylamide derivatives and nephritis remedies and tgf-.beta. inhibitors containing the same
US8507682B2 (en) Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (S1P2) receptors
CA2696429A1 (en) Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
WO1998049152A1 (en) Protease inhibitors
WO2008030838A2 (en) Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist biological activity
FI95372B (en) The process prepares therapeutically valuable arylsulfonamides
MX2012005189A (en) Ire-1 î± inhibitors.
US20060128757A1 (en) Pyridine derivatives useful as cyclooxygenase inhibitor
EP2269988B1 (en) Anthranilic acid amides and pharmaceutical use thereof
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
Patel et al. Synthesis, characterization and antimicrobial activity of some 4-aryl-2, 6-di (coumarin-3-yl) pyridines
AU2006240217A1 (en) Phenyl ethyne compounds
US8168795B2 (en) Selective sphingosine-1-phosphate receptor antagonists
WO2011008475A1 (en) Optionally substituted 2-(arylmethyl, aryloxy or arylthio) -n- pyridin-2 -yl-aryl acetamide or 2, 2-bis (aryl) -n-pyridin-2-yl acetamide compounds as medicaments for the treatment of eye diseases
US4767865A (en) 3'-pyridinylalkylinden- and 3'-pyridinylalkylindol-2-carboxylic acids and analogs
US4337253A (en) 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic
HRP20050239A2 (en) 2 thio-substituted imidazole derivates and their use in pharmacy
US4882433A (en) 3'-pyridinylalkylinden- and 3'-pyridinylalkylindol-2-carboxylic acids and analogs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090319

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20120117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120403